Page 1 Extracted Terms:
- Chronic Coronary Disease  
- Chronic Coronary Disease guideline  
- Stable Ischemic Heart Disease  
- Diagnosis and Management of Stable Ischemic Heart Disease  
- Coronary disease  
- Ischemic heart disease  
- Coronary angiography  
- Cardiovascular interventions  
- Cardiovascular disease  
- Cardiac management strategies  
- Clinical practice guidelines for coronary disease  
- Heart disease prevention and therapy terms (e.g., lipid management, anti‑platelet therapy, statins)

Page 2 Extracted Terms:
Acute coronary syndrome  
Angina  
Antiplatelet therapy  
Aspirin  
Atherosclerosis  
Cardiac events  
Cardiac rehabilitation  
Cardiovascular diseases  
Colchicine  
Coronary artery disease  
Coronary disease  
Dual antiplatelet therapy  
Fibrinolytic agents  
Factor Xa inhibitors  
Glucagon‑like peptide‑1 receptor agonists  
Hypercholesterolemia  
Hypertension  
Ischemic heart disease  
Ischemia with non‑obstructive coronary arteries  
Myocardial ischemia  
Secondary prevention  
Sodium‑glucose cotransporter‑2 inhibitors  
Spontaneous coronary artery dissection  
Heart disease risk factors  
Heart failure (preserved or reduced ejection fraction)  
Lifestyle risk factors (e.g., smoking cessation, diet, exercise tolerance, alcohol and substance use, environmental exposures)  
Guideline‑directed management and therapy  
Evaluation, diagnosis, and risk stratification  
Revascularization (PCI vs CABG)  
Percutaneous coronary intervention (PCI)  
Coronary artery bypass grafting (CABG)  
Chronic management after spontaneous coronary artery dissection (SCAD)  
Lipid management (statins, etc.)  
Blood pressure management (renin–angiotensin–aldosterone system inhibitors, beta‑blockers)  
Medical therapy for relief of angina  
Management of refractory angina  
Chelation therapy  
Cardiac rehabilitation (exercise training, education)  
Medical therapy to prevent cardiovascular events  
Immunizations (in the context of cardiovascular risk)  
Special populations (e.g., CAD with valvular heart disease, HF with preserved or reduced EF)

Page 3 Extracted Terms:
- Chronic Coronary Disease (CCD)  
- Cardiovascular Disease (CVD)  
- Coronary Artery Disease (CAD)  
- Myocardial Infarction  
- Left Ventricular Ejection Fraction  
- Cardiac Allograft Vasculopathy  
- Heart Transplant Recipient  
- Cardiac Rehabilitation  
- β‑Blocker (beta‑blocker)  
- Calcium Channel Blocker  
- Anti‑anginal Therapy  
- Statin  
- Ezetimibe  
- PCSK9 Inhibitor  
- Inclisiran  
- Bempedoic Acid  
- Dual Antiplatelet Therapy (DAPT)  
- Non‑prescription Dietary Supplement  
- Fish Oil  
- Omega‑3 Fatty Acids  
- Vitamins (as supplements)  
- Anatomic or Ischemic Testing  
- Smoking Cessation  
- Nicotine Replacement Therapy (NRT)  
- E‑cigarettes  
- Exercise (Aerobic & Resistance)  
- Healthy Dietary Habits  
- Team‑Based Care  
- Patient‑Centered Care  
- Social Determinants of Health  
- Shared Decision‑Making  
- Risk Assessment  
- Diagnostic Testing  
- Medical Treatment

Page 4 Extracted Terms:
- Chronic Coronary Disease  
- Guideline‑Directed Management and Therapy (GDMT)  
- Clinical evaluation  
- Diagnostic testing  
- Pharmacological treatment  
- Procedural treatments  
- Drug treatment regimens  
- Medical devices  
- Heart disease  
- Cardiovascular disease  
- AHA/ACC/ACC‑AHA joint guideline methodology  
- Randomized Controlled Trials (RCTs)  
- Systematic review  
- Evidence‑based guideline  
- Shared decision‑making  
- Patient engagement  
- Adherence to recommendations  
- Cost‑value considerations  
- Risk‑benefit assessment  
- Clinical outcomes measurement  

Page 5 Extracted Terms:
- Chronic Coronary Disease (CCD)  
- Coronary artery disease  
- Ischemic heart disease (stable ischemic heart disease)  
- Acute coronary syndrome  
- Angina  
- Cardiac rehabilitation  
- Cardiovascular diseases (CVD)  
- Dual antiplatelet therapy  
- Factor Xa inhibitors  
- Hypertension  
- Secondary prevention  
- Lipid management  
- SGLT2 inhibitors  
- GLP‑1 receptor agonists  
- Revascularization  
- Cost‑value considerations  
- Quality‑adjusted life years (QALY)  
- Incremental cost‑effectiveness ratio (ICER)  
- Clinical practice guidelines  
- Shared decision‑making  
- Team‑based care  
- Diabetes (type 2)  
- Diet / diet therapy / dietary supplements  
- Drug therapy  

These terms capture the core heart‑disease concepts and therapeutic/intervention areas addressed in the guideline.

Page 6 Extracted Terms:
- Chronic Coronary Disease (CCD)  
- Acute Coronary Syndromes (ACS)  
- Coronary Artery Disease (CAD)  
- Left Ventricular (LV) Systolic Dysfunction  
- Cardiomyopathy (ischemic origin)  
- Stable Angina  
- Angina Symptoms (dyspnea, arm pain with exertion)  
- Coronary Vasospasm  
- Microvascular Angina  
- Coronary Computed Tomography Angiography (CTA)  
- Stress Test (screening study)  
- Atherosclerotic Cardiovascular Disease (ASCVD)  
- Heart Failure (HF)  
- Cardiovascular Events (future ASCVD–related events)  
- Symptom Relief  
- Quality of Life (QOL)  
- Diagnostic Evaluation  
- Risk Stratification  
- Revascularization  
- Primary Care Clinician Role  
- Cardiology Specialist Role  
- Evidence‑Based Medical Therapy  
- Lifestyle Modification  
- Shared Decision‑Making  
- Coronary Calcium Score (on CT)  
- Atherosclerosis Risk Reduction  
- Follow‑up and Monitoring  
- Cost and Value Considerations  
- Future Research Needs (CCD)

Page 7 Extracted Terms:
- Atherosclerotic cardiovascular disease (ASCVD)  
- Atherosclerotic cardiovascular disease (ASCVD)  
- Chronic coronary disease (CCD)  
- Coronary artery disease (CAD)  
- Coronary heart disease (CHD)  
- Cardiovascular disease (CVD)  
- Coronary artery disease (CAD)  
- Stable ischemic heart disease  
- Stable coronary artery disease (stable CAD)  
- Acute coronary syndrome (ACS) – implied by “coronary artery disease”  
- Atrial fibrillation (AF)  
- Ventricular arrhythmias (VT)  
- Sudden cardiac death (SCD)  
- Heart failure (HF)  
- Valvular heart disease (VHD)  
- Peripheral arterial disease (PAD) – implied by “atherosclerotic disease”  
- Hypertension (high blood pressure)  
- Elevated blood pressure / high blood pressure  
- Hypertriglyceridemia  
- Diabetes mellitus type 2 (T2DM)  
- Hypercholesterolemia (high cholesterol)  
- Dyslipidemia – overall cholesterol/lipid disorders  
- Coronary artery revascularization (e.g., percutaneous coronary intervention [PCI], coronary artery bypass grafting)  
- Primary prevention of cardiovascular disease  
- Secondary prevention of cardiovascular disease  
- Dual antiplatelet therapy (DAPT)  
- Anticoagulant therapy (e.g., warfarin, DOACs)  
- Antiplatelet therapy (e.g., aspirin, clopidogrel)  
- Statins (HMG‑CoA reductase inhibitors)  
- Lipid‑lowering agents (e.g., ezetimibe, PCSK9 inhibitors)  
- Cardiac rehabilitation  
- Exercise training – core component of cardiac rehabilitation  
- Dietary pattern for heart health (e.g., Mediterranean diet)  
- Drug‑drug interactions affecting statin use  
- Cardio‑oncology drug interactions  
- Smoking / tobacco cessation – major cardiovascular risk factor  
- Air pollution – cardiovascular risk factor  
- Exercise guidance for patients with heart disease  
- Clinical management of stable coronary artery disease (CAD)  
- Clinical management of heart failure (HF)  
- Cardiovascular considerations in pregnancy  
- Cardiovascular considerations in HIV infection  
- Psychological health in cardiovascular disease (mind‑heart connection)  
- Life’s Essential 8 (cardiovascular health metrics)  
- Assessment of chest pain for coronary artery disease (CAD)  
- Evaluation and diagnosis of chest pain (clinical guideline)  

*(All terms directly extracted or closely inferred from the guideline titles and descriptions in the provided text.)*

Page 8 Extracted Terms:
- Chronic Coronary Disease  
- Coronary Disease  
- Heart Disease  
- AHA/ACC/ACCP/ASPC/NLA/PCNA (cardiology guideline alliance)  
- Circulation (journal title, cardiology focus)  
- Class of Recommendation (COR)  
- Level of Evidence (LOE)  
- PICO[TS] structure (clinical question format)  
- Clinical trial evidence  
- Intervention (cardiac care)  
- Diagnostic testing (cardiology)  
- Drug classification (cardiac therapy)  
- Device classification (cardiac devices)

Page 9 Extracted Terms:
- Angiotensin‑converting enzyme (ACE)  
- Acute coronary syndrome (ACS)  
- Atrial fibrillation (AF)  
- Angiotensin‑receptor blocker (ARB)  
- Atherosclerotic cardiovascular disease (ASCVD)  
- Body mass index (BMI)  
- Blood pressure (BP)  
- Coronary artery bypass grafting (CABG)  
- Coronary artery disease (CAD)  
- Calcium channel blocker (CCB)  
- Chronic coronary disease (CCD)  
- Coronary heart disease (CHD)  
- Chronic kidney disease (CKD)  
- Cardiovascular magnetic resonance (CMR)  
- Coronavirus Disease 2019 (COVID‑19)  
- Cardiac rehabilitation (CR)  
- Cardiovascular disease (CVD)  
- Computed tomography angiography (CTA)  
- Coronary CT angiography (CCTA)  
- Dual antiplatelet therapy (DAPT)  
- Direct oral anticoagulant (DOAC)  
- Electrocardiogram (ECG)  
- Estimated glomerular filtration rate (eGFR)  
- Familial hypercholesterolemia (FH)  
- Fractional flow reserve (FFR)  
- Guideline‑directed management and therapy (GDMT)  
- Glucagon‑like peptide‑1 (GLP‑1)  
- High‑density lipoprotein (HDL)  
- Heart failure (HF)  
- Human immunodeficiency virus (HIV)  
- Instantaneous wave‑free ratio (iFR)  
- Ischemia with non‑obstructive coronary artery (INOCA)  
- Low‑density lipoprotein (LDL)  
- Left ventricular (LV)  
- Left ventricular ejection fraction (LVEF)  
- Major adverse cardiovascular event (MACE)  
- Myocardial blood flow reserve (MBFR)  
- Myocardial perfusion imaging (MPI)  
- Myocardial infarction (MI)  
- Nicotine replacement therapy (NRT)  
- Platelet adenosine diphosphate receptor (P2Y12)  
- Positron emission tomography (PET)  
- Percutaneous coronary intervention (PCI)  
- Proprotein convertase subtilisin/kexin type 9 (PCSK9)  
- Proton pump inhibitor (PPI)  
- Quality of life (QOL)  
- Renin‑angiotensin‑aldosterone system inhibitor (RAASi)  
- Randomized controlled trial (RCT)  
- Single antiplatelet therapy (SAPT)  
- Spontaneous coronary artery dissection (SCAD)  
- Social determinants of health (SDOH)  
- Sodium glucose cotransporter 2 (SGLT2)  
- Single‑photon emission computed tomography (SPECT)  
- Transient ischemic attack (TIA)  

*Key clinical concepts from the text:*  
- Chronic stable angina pectoris  
- Coronary artery disease  
- Ischemic heart disease  
- Atherosclerotic cardiovascular disease  
- Coronary heart disease  
- Myocardial infarction (MI)  
- Angiographic chronic coronary disease (CCD)

Page 10 Extracted Terms:
- Coronary Heart Disease (CHD)  
- Myocardial Infarction (MI)  
- Angina / Angina Pectoris  
- Chest pain / Chest discomfort (AP)  
- Insufficient blood flow to the heart muscle  
- Rose Angina (Rose questionnaire)  
- Stable Angina Pectoris  
- Glucose‑Cotransporter‑2 (SGLT2) inhibitors  
- Glucagon‑like peptide‑1 (GLP‑1) receptor agonists  
- Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) inhibitors  
- Bempezoic acid  
- Inclisiran  
- Prevalence of CHD  
- Confidence interval (CI)  
- National Health and Nutrition Examination Survey (NHANES)  
- National Behavioral Risk Factor Surveillance System (BRFSS)  
- American Heart Association (AHA)  
- American College of Cardiology (ACC)  
- American College of Preventive Cardiology (ACCP)  
- American Society for Preventive Cardiology (ASPC)  
- National Heart, Lung, and Blood Institute (NHLBI)

Page 11 Extracted Terms:
- Chronic Coronary Disease (CCD)  
- Coronary Heart Disease (CHD)  
- Angina  
- Diagnostic approaches for coronary disease  
- Risk stratification in coronary disease  
- Treatment approaches for chronic coronary disease  
- Shared decision‑making (in cardiovascular care)  
- Team‑based care (in cardiovascular management)  
- Cost and value considerations in cardiovascular therapy  
- Global Burden of Disease data on coronary disease  
- Behavioral Risk Factor Surveillance System (BRFSS) data on coronary disease prevalence  
- Prevalence of angina or CHD  

 *(All terms are directly associated with heart disease and its clinical management as highlighted in the guideline excerpt.)*

Page 12 Extracted Terms:
**Key heart‑disease terms extracted from the guideline text**

1. Chronic Coronary Disease (CCD)  
2. Myocardial ischemia  
3. Angina (stable chest pain)  
4. Functional capacity  
5. Guideline‑directed medical therapy (GDMT)  
6. Stress positron emission tomography (PET)  
7. Single‑photon emission computed tomography myocardial perfusion imaging (SPECT MPI)  
8. Cardiovascular magnetic resonance imaging (CMR)  
9. Stress echocardiography  
10. Invasive coronary angiography (ICA)  
11. Nuclear myocardial perfusion imaging (MPI)  
12. Exercise treadmill testing  
13. Myocardial blood flow reserve (MBFR)  
14. Coronary CT angiography (CCTA)  
15. Bypass graft (coronary artery bypass graft, CABG)  
16. Stent patency  
17. Coronary revascularization  
18. Percutaneous coronary intervention (PCI)  
19. Left main stenosis  
20. Left ventricular ejection fraction (LVEF)  
21. Major adverse cardiovascular events (MACE)  
22. Cardiovascular death  
23. Non‑fatal myocardial infarction (MI)  
24. Wall‑motion abnormality  
25. Late gadolinium enhancement  
26. Revascularization strategy  
27. Ischemic burden  
28. Cardiac risk stratification  
29. Diagnostic accuracy  
30. Stress testing  
31. Coronary artery disease (CAD)  
32. Non‑obstructive coronary arteries (INOCA)  
33. Ischemia extent  
34. Ischemia severity  
35. Clinical decision‑making  
36. Diagnostic evaluation  
37. Stress‑induced ischemia  

These terms capture the key concepts, diagnostic modalities, therapeutic options, and outcome markers discussed in the text.

Page 13 Extracted Terms:
- Chronic Coronary Disease (CCD)  
- Coronary Artery Disease (CAD)  
- Major Adverse Cardiovascular Events (MACE)  
- Cardiovascular death  
- Myocardial infarction (MI)  
- Hospitalization for unstable angina  
- Heart failure (HF)  
- Resuscitated cardiac arrest  
- Guideline‑directed medical therapy (GDMT)  
- Invasive coronary angiography (ICA)  
- Revascularization (e.g., PCI, CABG)  
- Fractional flow reserve (FFR)  
- Computed tomography coronary angiography (CCTA)  
- Positron emission tomography myocardial perfusion imaging (PET MPI)  
- Single photon emission computed tomography myocardial perfusion imaging (SPECT MPI)  
- Myocardial blood flow reserve (MBFR)  
- Cardiopulmonary exercise testing / treadmill testing  
- Duke Treadmill Score  
- Left ventricular (LV) systolic dysfunction  
- Left main coronary artery disease  
- Noninvasive cardiac testing  
- Cardiac rehabilitation (CR)  
- Ischemia severity (noninvasive testing)  
- Bypass graft patency  
- Epicardial coronary arteries  
- Coronary microvascular disease  
- Risk stratification scores (validated risk models)  
- Event‑free survival  

These are the principal concepts and diagnostic or therapeutic modalities that relate directly to heart disease as presented in the guideline text.

Page 14 Extracted Terms:
- Chronic Coronary Disease (CCD)  
- Coronary artery disease  
- Myocardial infarction (MI)  
- Angina  
- Coronary ischemia  
- Revascularization  
- Percutaneous coronary intervention (PCI)  
- Coronary artery bypass grafting (CABG)  
- Coronary computed tomography angiography (CCTA)  
- Cardiovascular magnetic resonance imaging (CMR)  
- Single‑photon emission computed tomography (SPECT)  
- Positron emission tomography (PET)  
- Duke Treadmill Score (DTS)  
- Electrocardiogram (ECG)  
- Exercise stress test (EST)  
- High‑sensitivity troponin  
- B‑type natriuretic peptide (BNP)  
- Left ventricular ejection fraction (LVEF)  
- Left ventricular hypertrophy (LVH)  
- Coronary flow reserve (CFR)  
- Coronary artery plaque burden  
- Napkin‑ring sign  
- Positive remodeling (remodeling index > 1.1)  
- Low‑attenuation plaque (mean CT < 30 HU)  
- Atrial fibrillation/flutter  
- Heart failure (HF)  
- Myocardial perfusion reserve  
- Myocardial blood flow at stress  
- Major adverse cardiovascular events (MACE)  
- Cardiovascular death  
- Non‑fatal MI  
- Cardiovascular hospitalization  
- Ischemic heart failure  
- Coronary artery stenosis  
- Coronary burden high‑risk plaque  
- Left bundle branch block (LBBB)  
- Resting heart rate  
- Peak rate‑pressure product  
- Coronary artery bypass graft (CABG) indication  
- Calcium score  
- Clinical outcomes (all‑cause death, all‑cause mortality)  
- Exercise intolerance  
- Peripheral artery disease (PAD)  
- Diabetes mellitus  
- Dyslipidemia  
- Chronic kidney disease (CKD)  
- Obesity / elevated body mass index (BMI)  
- Smoking (current or former)  
- Depression  
- Poor adherence to pharmacotherapy  
- Socio‑economic status / poverty / lack of health‑care access  
- Age  
- Male sex  
- Clinical trials / guidelines:  
 • ISCHEMIA  
 • COURAGE  
 • BARI‑2D  
 • STICH  
 • AHA/ACC/ACCP/ASPC/NLA/PCNA Chronic Coronary Disease Guideline  
 • 2021 AHA/ACC Chest Pain Guideline  
- Risk prediction factors and stratification categories  
- Functional and anatomic testing modalities  
- Ancillary imaging variables (e.g., CT‑fractional flow reserve)

Page 15 Extracted Terms:
- Chronic Coronary Disease (CCD)  
- Coronary revascularization  
- Percutaneous Coronary Intervention (PCI)  
- Medical therapy (including guideline‑directed medical therapy, GDMT)  
- LVEF ≤ 35%  
- Heart failure (HF)  
- Heart failure with preserved ejection fraction (HF‑pEF)  
- Non‑invasive modalities (e.g., myocardial perfusion imaging, stress testing)  
- Coronary computed tomographic angiography (CCTA)  
- Coronary ischemia  
- Coronary angiography  
- CAD (coronary artery disease)  
- Ischemic events (non‑fatal ischemia, myocardial infarction)  
- Atherosclerosis progression  
- Symptoms (angina, dyspnea, fatigue)  
- Functional status and limitation  
- Quality of life (QOL)  
- Antianginal medications  
- Antithrombotic therapy (antiplatelets/anticoagulants)  
- Lipid‑lowering therapy (statins, PCSK9 inhibitors)  
- Glycemic control (diabetes management)  
- Blood pressure control  
- Smoking cessation, physical activity, nutrition, weight management, stress reduction  
- Patient‑reported health status measures  
- Shared decision‑making  
- Remote disease‑management programs  
- Clinical follow‑up (annual, telehealth, in‑person)  
- Trials: REVIVED‑BCIS2, COURAGE, BARI 2D, ISCHEMIA.

Page 16 Extracted Terms:
- Chronic Coronary Disease (CCD)  
- Coronary disease  
- Atherosclerotic Cardiovascular Disease (ASCVD)  
- Angina  
- Ischemic symptoms  
- Cardiovascular disease  
- Heart disease  
- Seattle Angina Questionnaire (patient‑reported health status measure)  
- ASCVD risk factors  
- Quality of life (QOL) in cardiovascular patients  


Page 17 Extracted Terms:
- Chronic Coronary Disease (CCD)  
- Atherosclerotic Cardiovascular Disease (ASCVD)  
- Myocardial infarction (MI)  
- Recurrent myocardial infarction  
- Cardiovascular complications  
- Hypertension  
- Diabetes mellitus  
- Hyperlipidemia  
- Tobacco cessation (smoking cessation)  
- Weight loss  
- Depression (as a cardiovascular risk factor)  
- Tele‑health / remote patient monitoring  
- Patient education (on symptom management, lifestyle, medications)  
- Medication therapy management  
- Medication adherence  
- Symptom management  
- Lifestyle changes  
- Social determinants of health (SDOH) risk factors  
- Morbidity  
- Mortality  
- Readmission  
- Emergency department visits  
- Health‑related quality of life (QOL)  
- Cost‑effectiveness / cost‑efficiency  
- Health‑care resource utilization  
- Team‑based care  
- Decision support aids  
- Specialty clinics  
- Advanced practice providers (in care delivery)


Page 18 Extracted Terms:
- Chronic Coronary Disease (CCD)  
- Coronary disease  
- Cardiac symptoms  
- Recurrent myocardial infarction (MI)  
- Hospitalizations  
- Cardiovascular mortality  
- Low‑density lipoprotein cholesterol (LDL‑C)  
- Systolic blood pressure (BP)  
- Revascularization  
- Guideline‑directed medical therapy (GDMT)  
- Shared decision‑making  
- Medication adherence  
- Heart Quality of Life instrument  
- Pharmacist‑administered intervention  
- Motivational interviewing  
- Internet‑based education  
- Physical activity  
- Dietary habits  
- Smoking cessation  
- Health literacy  

These terms capture the primary heart‑disease concepts referenced in the guideline excerpt.

Page 19 Extracted Terms:
**Key Terms related to Heart Disease**

- Chronic Coronary Disease (CCD)  
- Cardiovascular disease (CVD)  
- Myocardial infarction (MI)  
- Stable angina  
- Revascularization  
- Percutaneous coronary intervention (PCI)  
- Antithrombotic therapy  
- Guideline‑Directed Medical Therapy (GDMT)  
- Secondary prevention  
- Cardiac rehabilitation (CR)  
- Heart‑healthy diet / Nutrition, including supplements  
- Physical activity / Exercise prescription  
- Cardiovascular outcomes  
- Risk–benefit tradeoff  
- Shared decision‑making  
- Decision aids (e.g., PCI Choice)  
- Social Determinants of Health (SDOH)  
- Health equity / Health disparities  
- Neighborhood disadvantage  
- Insurance status / Health insurance coverage  
- Economic stability / Financial strain  
- Transportation / Access to care  
- Health literacy  
- Mental health / Psychosocial stressors  
- Cultural humility  
- Patient–caregiver decision delegation  
- Clinical practice guidelines (AHA/ACC/ACCP/ASPC/NLA/PCNA)

Page 20 Extracted Terms:
**Key heart‑disease terms extracted:**

- Chronic Coronary Disease  
- CCD (Chronic Coronary Disease)  
- Coronary  
- Cardiovascular Care  

Page 21 Extracted Terms:
**Key heart‑disease related terms extracted from the text**

- Chronic Coronary Disease (CCD)  
- Cardiovascular Disease (CVD)  
- Atherosclerotic Cardiovascular Disease (ASCVD)  
- Heart Failure (HF)  
- Stroke  
- Cardiovascular events (acute CVD events)  
- Acute CVD deaths / CVD‑related deaths  
- Cardiometabolic health  
- Insulin resistance  
- Diabetes mellitus  
- Dyslipidemia  
- Hypertension  
- Obesity (overweight/obese patients)  
- Sodium intake (≤ 2300 mg/d, optimum 1500 mg/d)  
- Saturated fat (< 6 % of total calories)  
- Unsaturated fats (monounsaturated, polyunsaturated)  
- Trans fat (to be avoided)  
- Processed meats (cured bacon, hot dogs)  
- Refined carbohydrates (white bread, white rice, refined cereals)  
- Sugar‑sweetened beverages (soft drinks, energy drinks, fruit drinks)  
- Whole grains  
- Dietary fiber  
- Mediterranean‑type dietary plan (plant‑based, lean protein, fish)  
- Lifestyle modification / dietary behavior changes  
- Guideline‑Directed Management and Therapy (GDMT)  
- Nonprescription nutrition/dietary supplements  
- Omega‑3 fatty acids  
- Vitamins C, D, E, beta‑carotene  
- Calcium  
- Social Determinants of Health (SDOH)  
- Telehealth & digital interventions  
- Collaborative partnerships (health‑care systems & community organizations)  
- Lyon Diet Heart Study (Mediterranean diet intervention)   
- AHA/ACC/ACCP/ASPC/NLA/PCNA Chronic Coronary Disease Guideline  
- Chronic diseases (multiple chronic disease screening)

Page 22 Extracted Terms:
- Chronic Coronary Disease (CCD)  
- Cardiovascular Disease (CVD)  
- Coronary Heart Disease (CHD)  
- Atherosclerotic cardiovascular disease (ASCVD)  
- Low‑density lipoprotein cholesterol (LDL‑C)  
- High‑density lipoprotein cholesterol (HDL‑C)  
- Triglycerides  
- Blood pressure (BP)  
- Hypertension (HTN)  
- Sodium intake  
- Potassium intake  
- Saturated fatty acids  
- Trans fatty acids  
- Monounsaturated fatty acids  
- Polyunsaturated fatty acids  
- Dietary fiber  
- Simple carbohydrates (e.g., high‑fructose corn syrup)  
- Refined grains  
- Sugar‑sweetened beverages  
- Processed meats (smoked, cured, salted)  
- Plant‑based diet  
- Mediterranean diet  
- DASH (Dietary Approaches to Stop Hypertension) diet  
- Weight loss / obesity  
- Diabetes mellitus  
- Chronic kidney disease (CKD)  
- Insulin sensitivity  
- Lipoprotein profile  
- Biomarkers of cardiac injury, inflammation, and cardiac strain  
- Atherosclerotic plaque burden  
- Primary prevention  
- Secondary prevention  
- Dose‑response relationship (high‑quality carbohydrate intake)  
- Cardiometabolic profile  
- Lifestyle modification for cardiovascular health  
- Dose‑response relationship (saturated fat reduction)  


These terms capture the main dietary, metabolic, and clinical concepts related to heart disease discussed in the guideline excerpt.

Page 23 Extracted Terms:
- Chronic Coronary Disease (CCD)  
- Cardiovascular Disease (CVD)  
- Major Adverse Cardiac Events (MACE)  
- Coronary Heart Disease (CHD)  
- Acute Coronary Syndrome (ACS)  
- Omega‑3 fatty acid supplements  
- Icosapent ethyl (eicosapentaenoic acid ethyl ester)  
- Vitamin D supplementation  
- Antioxidant therapy (vitamin C, beta‑carotene, multivitamins)  
- Calcium supplementation (≥ 500 mg/d elemental calcium)  
- Mental health conditions (depression, anxiety, anger/hostility, general distress, type D personality)  
- Screening for mental health disorders  
- Pharmacologic therapy for mental health  
- Non‑pharmacologic therapy for mental health  
- Cardiovascular risk factors (blood pressure, lipids, body mass index, inflammation, thrombosis)  
- Health behaviors (medication adherence, cardiac rehabilitation, diet, physical activity, sleep, smoking)  
- Quality of Life (QOL)  
- Cardiovascular outcomes  
- Cardiovascular mortality  
- Cardiovascular event reduction  
- Cardiovascular event risk  
- Cardiovascular risk factor management  



Page 24 Extracted Terms:
- Chronic Coronary Disease (CCD)  
- Acute Coronary Syndrome (ACS)  
- Myocardial Infarction (MI)  
- Major Adverse Cardiovascular Events (MACE)  
- Cardiovascular Outcomes  
- Cardiac Rehabilitation (CR)  
- Depression (as a cardiovascular comorbidity)  
- Antidepressants (e.g., escitalopram)  
- ESCIPTACS (Escitalopram in Depressive Patients with Acute Coronary Artery Syndrome) study  
- TRIUMPH study (Treatment‑Resistant Hypertension)  
- Smoking Cessation (risk factor for heart disease)  
- Nicotine Replacement Therapy  
- Quitline (telephone‑based smoking cessation resource)

Page 25 Extracted Terms:
- Chronic Coronary Disease (CCD)  
- Cardiovascular Disease (CVD)  
- Coronary Heart Disease (CHD)  
- Myocardial Infarction (MI)  
- Revascularization  
- Atherosclerosis  
- Endothelial dysfunction  
- Thrombosis / pro‑thrombotic state  
- Heart rate  
- Blood pressure (BP)  
- Cardiovascular events  
- Cardiac mortality  
- Cardiac quality of life (QOL)  
- Smoking / tobacco use  
- Second‑hand smoke exposure  
- Nicotine‑replacement therapy (NRT)  
- Bupropion therapy  
- Varenicline therapy  
- E‑cigarette use  
- Depression, anxiety, and stress as cardiovascular risk factors  

These terms capture the core concepts related to heart disease discussed in the guideline text.

Page 26 Extracted Terms:
- Chronic Coronary Disease (CCD)  
- Coronary heart disease (CHD) / Coronary artery disease (CAD)  
- Congestive heart failure (CHF)  
- Atherosclerotic cardiovascular disease (ASCVD)  
- Cardiovascular disease (CVD)  
- Myocardial infarction (MI)  
- Ischemic heart disease (IHD)  
- Endothelial dysfunction  
- Vascular stiffness  
- Blood pressure (BP)  
- Smoking cessation (behavioral and pharmacologic)  
- Nicotine replacement therapy (NRT)  
- Varenicline  
- Bupropion  
- E‑cigarettes / electronic nicotine delivery systems (ENDS)  
- Secondhand smoke exposure  
- Nicotine dependence / addiction  
- Alcohol consumption (≤1 drink/day for women, ≤2 drinks/day for men)  
- Cardiovascular risk factors (e.g., smoking, alcohol, secondhand smoke)  
- Cardiovascular events (e.g., arrhythmias, heart failure episodes, MI)  
- Cardiovascular mortality (cardiovascular death)  
- Cardiovascular safety and risk assessment  
- Prevention and risk reduction guidelines (e.g., AHA/ACC/ACCP/ASPC/NLA/PCNA Chronic Coronary Disease Guideline)  
- Cardiovascular pharmacotherapy  
- Endothelial function tests  
- Cardiovascular policy (e.g., smoke‑free workplace policies)

Page 27 Extracted Terms:
**Key Heart‑Disease–Related Terms Extracted**

- Cardiovascular system  
- Chronic coronary disease (CCD)  
- Myocardial infarction (MI) / acute myocardial infarction  
- Cardiovascular risk / cardiovascular events  
- Cardiovascular mortality / death  
- Cardiovascular morbidity  
- Cardiac arrest  
- Cardiac toxicity  
- Cardiac‑specific effects of substances  
- Cardioprotective effects (light‑to‑moderate alcohol)  
- J‑shaped relationship between alcohol and cardiovascular risk  
- Heavy alcohol use  
- Binge drinking  
- Light‑to‑moderate alcohol consumption (5–25 g/d)  
- Sympathetic nervous system stimulation  
- Platelet activation / aggregation  
- Endothelial dysfunction  
- Myocardial oxygen demand  
- Drug‑drug interactions with cardiovascular therapies  
- Substance abuse (cocaine, amphetamines, opioids, marijuana/cannabis)  
- Cardiovascular therapies (pharmacologic agents, device therapies)

Page 28 Extracted Terms:
- Chronic Coronary Disease (CCD)  
- Cardiovascular disease (CVD)  
- Myocardial infarction (MI)  
- Coronary events  
- Hypertension  
- Mortality rate  
- Recurrent cardiovascular events  
- Alcohol consumption (light‑to‑moderate)  
- Binge drinking  
- J‑shaped relationship (alcohol vs. cardiovascular outcomes)  
- Cancer risks associated with alcohol  
- Cardiac rehabilitation (CR)  
- Regular exercise  
- Sexual activity (as moderate exercise)  
- Sexual dysfunction  
- Phosphodiesterase type 5 inhibitors (PDE5i)  
- Nitrate medications  
- Severe hypotension (risk with PDE5i + nitrates)  
- Percutaneous coronary intervention (PCI)  
- Coronary artery bypass grafting (CABG)  
- Femoral access (PCI)  
- Radial access (PCI)  
- Sternal‑sparing surgery (CABG)  
- Angina  
- Metabolic equivalents (METs)  
- Unstable or decompensated CCD  
- Erectile function (International Index of Erectile Function)  
- Physical exercise training (within CR)  
- Pelvic floor exercise  
- Psychoeducation  
- Long‑acting nitrates  
- Short‑acting nitrates (e.g., nitroglycerine)  
- Sildenafil  
- Vardenafil  
- Tadalafil  
- Global Burden of Disease (GBD) study  
- Determinants of Myocardial Infarction Onset Study  
- Prospective Epidemiological Study of Myocardial Infarction (PRIME)

Page 29 Extracted Terms:
**Key heart‑disease related terms from the guideline excerpt**

- Chronic Coronary Disease (CCD)  
- High‑intensity statin therapy  
- Moderate‑intensity statin therapy  
- Low‑density lipoprotein cholesterol (LDL‑C)  
- High‑density lipoprotein cholesterol (HDL‑C)  
- Major Adverse Cardiovascular Events (MACE)  
- Ezetimibe  
- PCSK9 monoclonal antibody  
- Icosapent ethyl (EPA ethyl ester)  
- Bempedoic acid  
- Inclisiran  
- Niacin  
- Fenofibrate  
- Omega‑3 fatty acids  
- Atherosclerotic disease  
- Lipid management  
- Lipid‑lowering medication  
- Maximal tolerated statin therapy  
- Generic statin formulation  
- Lipid monitoring (fasting lipids, triglycerides)  
- Residual cardiovascular risk  
- Cardiovascular morbidity  
- Cardiovascular mortality  
- Cholesterol Treatment Trialists (CTT) meta‑analysis  
- Randomized controlled trials (RCTs)  

These terms capture the central concepts, therapies, and outcomes discussed in the clinical guideline.

Page 30 Extracted Terms:
- LDL‑C (low‑density lipoprotein cholesterol)  
- Statin therapy (high‑intensity, moderate‑intensity, low‑intensity)  
- Statin intolerance (partial/complete)  
- Nocebo effect (patient expectation of harm with statin)  
- ASCVD (atherosclerotic cardiovascular disease)  
- Cardiovascular events (e.g., MI, stroke, peripheral artery disease)  
- Acute coronary syndrome (ACS)  
- Myocardial infarction (MI)  
- Ischemic stroke  
- Symptomatic peripheral artery disease (ABI < 0.85)  
- Ankle‑brachial index (ABI)  
- Familial hypercholesterolemia  
- Congestive heart failure / heart failure  
- Ezetimibe (add‑on therapy)  
- Lipid‑lowering therapy (statins, ezetimibe, combination therapy)  
- Cholesterol guideline (e.g., 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Chronic Coronary Disease Guideline)  
- LDL‑C threshold for therapy intensification (≥ 70 mg/dL, persistent ≥ 100 mg/dL)  
- LDL‑C reduction goals (≥ 50 % with high‑intensity statin)  
- Friedewald equation (LDL‑C estimation)  
- Martin/Hopkins method (LDL‑C calculation)  
- Quality‑adjusted life years (QALY)  
- Cost‑effectiveness / cost‑saving of lipid‑lowering therapy  
- Chronic kidney disease (CKD) with eGFR 15–59 mL/min/1.73 m²  
- Hypertension  
- Diabetes mellitus  
- Current tobacco smoking  
- High‑risk conditions for ASCVD (age ≥ 65, familial hypercholesterolemia, prior coronary interventions, etc.)  
- Very high‑risk definition for future ASCVD events (history of multiple events or one major event plus ≥ 2 high‑risk conditions)  
- Lipoprotein apheresis (used in familial hypercholesterolemia)  

These are the principal terms related to heart disease and lipid management extracted from the provided text.

Page 31 Extracted Terms:
- Chronic Coronary Disease  
- Cardiovascular Disease (CVD)  
- Clinical Atherosclerotic Cardiovascular Disease (ASCVD)  
- Acute Coronary Syndrome (ACS)  
- Major Adverse Cardiovascular Events (MACE)  
- Cardiovascular events  
- Thrombolysis in Myocardial Infarction (TIMI) Risk Score for Secondary Prevention (TRS 2P)  
- Ezetimibe  
- PCSK9 monoclonal antibody (e.g., alirocumab, evolocumab)  
- Ezetimibe‑first strategy  
- Low‑density lipoprotein cholesterol (LDL‑C)  
- Non‑HDL‑C  
- LDL‑C thresholds: ≥70 mg/dL, <70 mg/dL, <50 mg/dL  
- Very high‑risk ASCVD (Table 10)  
- High‑intensity statin therapy  
- Moderate‑intensity statin therapy  
- Low‑intensity statin therapy  
- Atorvastatin (10 mg, 20 mg, 40 mg, 80 mg)  
- Rosuvastatin (5 mg, 10 mg, 20 mg, 40 mg)  
- Simvastatin (10 mg, 20 mg, 40 mg)  
- Pravastatin (10 mg, 20 mg, 40 mg, 80 mg)  
- Lovastatin (20 mg, 40 mg, 80 mg)  
- Fluvastatin (oral extended release, 40 mg, 80 mg, BID)  
- Pitavastatin (1–4 mg)  
- FOURIER trial (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk)  
- ODYSSEY OUTCOMES trial (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment with Alirocumab)  
- Cost‑effectiveness (cost‑per‑QALY, <$50,000/QALY)  
- Neurocognitive adverse effects  
- Myopathy, rhabdomyolysis  
- ASCVD risk calculators / risk factors (high‑risk clinical factors)  
- Lifetime major adverse cardiovascular events reduction ("fewer lifetime MACE")  
- Cardiovascular events reduction percentages (15 %, 19 %, etc.)  
- Absolute risk reduction (e.g., 1.5 %, 0.6 %)  
- Relative risk reduction (e.g., 15 %, 19 %)  
- Incremental Decrease through Aggressive Lipid Lowering (IDEAL) study  
- FDA labeling for statins (therapeutic recommendations)  

These terms capture the key concepts and entities in the text that relate directly to heart disease management and outcomes.

Page 32 Extracted Terms:
- Atherosclerotic cardiovascular disease (ASCVD)  
- Chronic coronary disease (CCD)  
- Major adverse cardiovascular events (MACE)  
- Coronary artery disease (CAD)  
- PCSK9 monoclonal antibody (PCSK9 mAb)  
- Statin therapy  
- Ezetimibe  
- Bempedoic acid  
- Inclisiran  
- Low‑density lipoprotein cholesterol (LDL‑C)  
- High‑density lipoprotein cholesterol (HDL‑C)  
- Triglycerides (TG)  
- Absolute risk reduction  
- Cardiovascular risk (high‑risk, very high‑risk)  
- Cost‑effectiveness in cardiovascular care  
- Randomized controlled trial (RCT) – in the context of cardiovascular studies

Page 33 Extracted Terms:
- Atherosclerotic cardiovascular disease (ASCVD)  
- Acute coronary syndrome (ACS)  
- Coronary artery disease (CAD)  
- Peripheral artery disease (PAD)  
- Familial hypercholesterolemia (FH)  
- Cardiovascular events (CV events)  
- Major adverse cardiovascular events (MACE)  
- Cardiovascular death  
- Myocardial infarction  
- Stroke/ischemic cerebrovascular event  
- Dyslipidemia (triglycerides, LDL‑C, HDL‑C)  
- Hypertriglyceridemia  
- Low‑density lipoprotein cholesterol (LDL‑C)  
- Elevated triglyceride levels  
- Non‑statin lipid‑lowering therapies  
- Statins (high‑intensity, moderate‑intensity, low‑intensity)  
- PCSK9 inhibitors (monoclonal antibodies)  
- PCSK9 monoclonal antibody therapy  
- PCSK9‑directed small interfering RNA (inclisiran)  
- Ezetimibe  
- Bempedoic acid  
- Icosapent ethyl (purified EPA)  
- Omega‑3 fatty acids (EPA, DHA)  
- Eicosapentaenoic acid (EPA)  
- Dihomo‑γ‑linolenic acid (DHA)  
- Mineral oil placebo  
- Corn oil placebo  
- EPA/DHA plasma levels  
- Cardiovascular risk (high, very high, moderate)  
- Primary prevention  
- Secondary prevention  
- Shared decision‑making  
- Incremental cost‑effectiveness ratio  
- Adverse events (e.g., tendon rupture, increased uric acid, atrial fibrillation)  

**Key clinical trials mentioned**  
- REDUCE‑IT (Reduction of Cardiovascular Events with Icosapent Ethyl)  
- RESPECT‑EPA (Randomized Trial for Evaluation in Secondary Prevention Efficacy of Combination Therapy – Statin and Eicosapentaenoic Acid)  
- STRENGTH (Long‑Term Outcomes Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia)  

These terms capture the major cardiovascular concepts, therapies, risk factors, and evidence referenced in the guideline text.

Page 34 Extracted Terms:
**Key terms related to heart disease:**

- Chronic Coronary Disease (CCD)  
- Atherosclerotic Cardiovascular Disease (ASCVD)  
- Statin therapy / Severe statin‑associated side effects  
- Inclisiran (monoclonal antibody)  
- Heterozygous Familial Hypercholesterolemia (FH)  
- Omega‑3 fatty acids (fish oil)  
- Major Adverse Cardiovascular Events (MACE)  
- Icosa­pent ethyl (EPA‑only formulation)  
- AIM‑HIGH trial  
- Extended‑release niacin  
- HPS2‑THRIVE trial (niacin + laropiprant)  
- ACCORD‑LIPID trial (fenofibrate)  
- Fenofibrate  
- PPARα modulator (pemafibrate)  
- PROMINENT trial  
- Hypertriglyceridemia (≥500 mg/dL)  
- Acute pancreatitis (risk from hypertriglyceridemia)  
- Blood pressure (BP)  
- Hypertension  
- BP targets (<130/<80 mm Hg, 120‑129/<80 mm Hg)  
- Cardiovascular disease (CVD) events  
- All‑cause death  
- Angiotensin‑converting enzyme (ACE) inhibitors  
- Angiotensin‑receptor blockers (ARBs)  
- Beta‑blockers  
- Dihydropyridine calcium channel blockers (CCBs)  
- Long‑acting thiazide diuretics  
- Mineralocorticoid receptor antagonists  
- Lifestyle modifications (weight loss, heart‑healthy diet, sodium reduction, physical activity, alcohol moderation)  
- HOPE trial (ramipril)  
- Rossipril (ramipril)  
- MI (myocardial infarction)  
- Stroke  
- CAD (coronary artery disease)  
- INVEST trial (international recommendations for BP management)  
- Multisociety Guideline for Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults  
- All‑cause mortality  
- Cardiovascular mortality  
- Lifestyle‑related blood‑pressure factors  
- Diabetes mellitus type 2 (as a cardiovascular risk factor)  

*(The list includes disease entities, therapeutic agents, clinical trials, risk factors, and management targets pertinent to cardiovascular health.)*

Page 35 Extracted Terms:
- Chronic Coronary Disease (CCD)  
- Cardiovascular disease (CVD)  
- Cardiovascular morbidity  
- Cardiovascular mortality (CVD death)  
- Myocardial infarction (MI)  
- Angina  
- Cardiac arrest  
- CVD events  
- β‑blockers (beta blockers)  
- ACE inhibitors (angiotensin‑converting enzyme inhibitors)  
- ARB agents (angiotensin II receptor blockers)  
- Calcium‑channel blockers (CCBs)  
- Thiazide diuretics  
- Mineralocorticoid receptor antagonists  
- SGLT2 inhibitors (sodium‑glucose cotransporter‑2 inhibitors)  
- GLP‑1 receptor agonists (glucagon‑like peptide‑1 receptor agonists)  
- Major adverse cardiovascular events (MACE)  
- Hypertension  
- Blood pressure (BP)  
- Systolic blood pressure (SBP)

Page 36 Extracted Terms:
- Chronic Coronary Disease (CCD)  
- Type 2 Diabetes (in the context of CCD)  
- SGLT2 inhibitors  
- GLP‑1 receptor agonists  
- Heart Failure (HF)  
- Left Ventricular Ejection Fraction (LVEF)  
- Cardiovascular death  
- Heart‑failure hospitalization  
- Quality of life (QOL)  
- Guideline‑Directed Medical Therapy (GDMT)  
- Major Adverse Cardiovascular Events (MACE)  
- Myocardial infarction (MI)  
- Stroke  
- Atherosclerosis / atherosclerotic events  
- Coronary Artery Disease (CAD)  
- Glycemic control (HbA1c targets)  
- Weight loss (as a benefit)  
- Kidney disease progression (as a benefit)  
- Hypoglycemia risk  
- Cost‑effectiveness / value assessment (high/intermediate)  
- Quality‑adjusted life year (QALY)  

These terms capture the principal concepts related to heart disease discussed in the guideline excerpt.

Page 37 Extracted Terms:
**Key Terms Related to Heart Disease**

- Chronic Coronary Disease (CCD)  
- Heart Failure (HF)  
- Heart Failure with Reduced Ejection Fraction (HFrEF)  
- Heart Failure with Preserved Ejection Fraction (HFpEF)  
- Sodium‑glucose co‑transporter‑2 (SGLT2) inhibitors  
- Empagliflozin  
- Dapagliflozin  
- SGLT2 inhibitor pharmacodynamics in HF  
- Cardiovascular death  
- HF hospitalization  
- Quality of life (QOL) and functional capacity in HF  
- Glucagon‑like peptide‑1 (GLP‑1) receptor agonists  
- Semaglutide  
- Liraglutide  
- Diabetes mellitus type 2 and its interaction with HF  
- Cardio‑renal considerations (eGFR, CKD stage)  
- Cost‑effectiveness (QALYs, incremental cost‑effectiveness ratio)  
- Guideline‐based risk factors: BMI, waist circumference, weight management  
- Hemodynamic parameters: ejection fraction, reduced vs preserved ejection fraction  

These terms capture the major clinical concepts, therapeutic agents, patient subgroups, outcome measures, and guideline‑specific recommendations discussed in the cited text.

Page 38 Extracted Terms:
- Chronic Coronary Disease (CCD)  
- Cardiovascular risk factor  
- Obesity  
- Severe obesity  
- Bariatric procedure / bariatric surgery  
- Sympathomimetic weight‑loss drugs  
- Atherosclerosis  
- Cardiac function  
- Myocardium  
- Vasculature  
- Hypertension (high blood pressure)  
- Dyslipidemia  
- Type 2 diabetes  
- Body Mass Index (BMI)  
- Waist circumference  
- Visceral adiposity  
- Cardiometabolic risk  
- Weight loss  
- Lifestyle modification  
- Nutrition  
- Physical activity / exercise  
- Behavioral counseling  
- SGLT2 inhibitors  
- GLP‑1 receptor agonists  
- Metabolic risk profile  
- Hemodynamic risk profile  
- Cardiovascular outcomes  
- Cardiac rehabilitation  
- Nutritional counseling  
- Blood pressure management  
- Lipid management  
- Diabetes management  
- Tobacco cessation  
- Psychosocial management  
- Exercise training  
- Cardiorespiratory fitness  
- Lean mass  
- Weight assessment  
- Body composition  
- Central obesity  

Page 39 Extracted Terms:
- Chronic Coronary Disease (CCD)  
- Cardiovascular disease (CVD)  
- Cardiovascular safety  
- GLP‑1 receptor agonist  
- Semaglutide  
- Tirzepatide (LY3298176)  
- Liraglutide  
- Major Adverse Cardiovascular Events (MACE)  
- Atherosclerotic cardiovascular disease (ASCVD)  
- Type 2 diabetes mellitus  
- Bariatric procedure  
- Gastric bypass surgery  
- Cardiac rehabilitation  
- Myocardial infarction (MI)  
- Stroke  
- Coronary artery bypass grafting (CABG)  
- Percutaneous coronary intervention (PCI)  
- Heart transplant  
- Spontaneous coronary artery dissection  
- Naltrexone/bupropion (weight‑loss drug)  
- Sibutramine  
- Phentermine  
- Diethylpropion  
- Benzphetamine  
- Phendimetrazine  
- Weight‑loss drugs  
- STEP 8 trial  
- SURMOUNT‑1 trial  
- SOS (Swedish Obese Subjects) study  
- Hazard ratio  
- Body mass index (BMI)  
- Obesity  
- Weight loss  
- Nonfatal MI  
- Nonfatal stroke  
- Cardiovascular deaths  
- Cardiovascular risk factors  
- Home‑based cardiac rehabilitation  
- Remote cardiac rehabilitation  
- Lifestyle therapy  
- Medication therapy

Page 40 Extracted Terms:
- Chronic Coronary Disease (CCD)  
- Cardiac Rehabilitation (CR)  
- Myocardial Infarction (MI)  
- Percutaneous Coronary Intervention (PCI)  
- Coronary Artery Bypass Grafting (CABG)  
- Stable Angina  
- Heart Transplant (HTx)  
- Cardiac Allograft Vasculopathy (CAV)  
- Spontaneous Coronary Artery Dissection (SCAD)  
- Heart Failure (HF)  
- Major Adverse Cardiovascular Events (MACE)  
- Rehospitalization (cardiovascular & non‑cardiovascular)  
- Mortality – cardiovascular, all‑cause  
- Functional Capacity  
- Quality of Life (QOL)  
- Moderate‑Intensity Aerobic Exercise (≥150 min/week)  
- High‑Intensity Interval Training (HIIT)  
- Resistance (Strength) Training (≥2 days/week)  
- Low‑Intensity Lifestyle Activity (walking breaks, reduced sedentary time)  
- Physical Activity Guidelines for CCD  
- Lipid Management  
- Blood Pressure Management  
- Sodium‑Glucose Co‑Transporter 2 Inhibitors (SGLT2i)  
- Glucagon‑Like Peptide‑1 Receptor Agonists (GLP‑1 RA)  
- Anti‑arteriosclerotic Effects  
- Anti‑arrhythmic Effects  
- Antithrombotic Effects  
- Anti‑ischemic Effects  
- Antidepressant Effects  
- Unstable Angina  
- Decompensated Heart Failure  
- Thromboembolic Disease  
- Uncontrolled Diabetes  
- End‑stage Cancer  
- Contraindications to Exercise (severe, life‑threatening, unstable conditions)  
- Risk Stratification (for CCD)  
- Team‑Based Approach (for CCD)  
- Patient Education (for CCD)  
- Shared Decision‑Making (for CCD)  
- Nutrition (including Supplements)  
- Mental Health (for CCD)  

Page 41 Extracted Terms:
- Chronic Coronary Disease (CCD)  
- Cardiovascular events  
- Cardiovascular outcomes  
- Ischemic heart disease  
- Acute myocardial infarction (MI)  
- Cardiometabolic risk  
- Air pollution  
- PM2.5 (particulate matter ≤ 2.5 µm)  
- Ambient air pollution  
- Extreme temperatures (heat and cold)  
- Heat wave  
- Wildfire smoke  
- Loop diuretics  
- Aerobic exercise (moderate‑intensity, vigorous‑intensity)  
- Resistance training (muscle‑strengthening)  
- Sedentary lifestyle  
- Lifestyle physical activities (e.g., gardening, office‑based movement, stair climbing)  
- Functional capacity  
- Quality of life (QOL)  
- Mortality rates  
- Cardiovascular mortality  
- Cardiovascular hospitalization  
- Urban heat island effect  
- Environmental noise  
- Health disparities  
- Racial and ethnic minority populations  
- Socioeconomic status  
- Ambient temperature exposure  
- Publicly available controlled‑temperature environments  
- AHA/ACC/ACCP/ASPC/NLA/PCNA Chronic Coronary Disease Guideline

(These terms capture the key clinical, environmental, and public‑health factors related to heart disease discussed in the text.)

Page 42 Extracted Terms:
**Key heart‑disease–related terms extracted from the text**

- Chronic Coronary Disease (CCD)  
- Coronary artery disease (CAD)  
- Myocardial infarction (MI)  
- Ischemic heart disease  
- Cardiac arrest  
- Percutaneous coronary intervention (PCI)  
- Dual antiplatelet therapy (DAPT)  
- Single antiplatelet therapy (SAPT)  
- Drug‑eluting stent (DES)  
- Major adverse cardiovascular events (MACE)  
- Thrombosis / atherothrombosis  
- Cardiovascular and cardiac events  
- Coronary artery bypass grafting (CABG)  
- Saphenous vein graft occlusion  
- Transient ischemic attack (TIA)  
- Intracranial hemorrhage (ICH)  
- Aspirin (low‑dose)  
- Clopidogrel (P2Y12 inhibitor)  
- Prasugrel (P2Y12 inhibitor)  
- Vorapaxar (PAR‑1 antagonist)  
- Non‑steroidal anti‑inflammatory drugs (NSAIDs)  
- Oral anticoagulants (e.g., warfarin, DOACs)  
- Direct oral anticoagulants (DOACs)  
- Rivaroxaban (low‑dose)  
- Proton pump inhibitor (PPI)  
- Bleeding risk  
- Thrombotic risk  
- Pre‑CIse DAPT (risk score)  
- DAPT risk score  
- PARIS risk score  
- Cardiovascular event prevention therapy  
- Coronary artery revascularization  
- Atherosclerotic disease

These terms capture the major clinical concepts, drugs, procedures, and risk assessment tools discussed in the guideline excerpt.

Page 43 Extracted Terms:
- Atrial fibrillation  
- Chronic coronary disease  
- Aspirin (acetylsalicylic acid)  
- Clopidogrel  
- Dual antiplatelet therapy (DAPT)  
- Platelet adenosine diphosphate receptor (P2Y12) agents  
- Direct oral anticoagulant (DOAC)  
- Rivaroxaban  
- Dabigatran  
- Apixaban  
- Edoxaban  
- Stent, drug‑eluting stent (DES)  
- Bare metal stent  
- Percutaneous coronary intervention (PCI)  
- Myocardial infarction (MI)  
- Stroke  
- Acute coronary syndrome (ACS)  
- Major adverse cardiovascular events (MACE)  
- Bleeding risk  
- Ischemic risk  
- Aspirin dosing: low-dose (81 mg) and high-dose (325 mg)  
- Single antiplatelet therapy (SAPT)  
- Oral anticoagulants (OAC)  
- Clinical guideline (AHA/ACC)  
- Meta‑analysis of randomized controlled trials (RCTs)  
- 2016 AHA/ACC guideline for DAPT  
- Clinical statements  
- 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Chronic Coronary Disease Guideline  
- 2023 Circulation journal (e.g., study pages e9–e119)  

Page 44 Extracted Terms:
- Dual Antiplatelet Therapy (DAPT)  
- Short‑term DAPT  
- Extended DAPT  
- Percutaneous Coronary Intervention (PCI)  
- Drug‑Eluting Stent (DES)  
- Stent Thrombosis  
- Myocardial Infarction (MI)  
- Acute Coronary Syndrome (ACS)  
- Coronary Artery Disease (CAD)  
- Chronic Coronary Disease (CCD)  
- Coronary Bypass Graft (CABG)  
- Left Main Coronary Artery Lesion  
- Bifurcation Lesion  
- Long Stent Length  
- Multileaf Lesion  
- Atherectomy  
- Chronic Occlusion  
- Aspirin (Low‑dose)  
- Clopidogrel  
- Ticagrelor  
- Prasugrel  
- P2Y12 Inhibitor  
- Platelet‑Activated Receptor‑1 (PAR‑1)  
- Vorapaxar (PAR‑1 antagonist)  
- Major Bleeding Complications  
- Major Adverse Cardiac Events (MACE)  
- Cardiovascular Death  
- Stroke (Cerebrovascular Event)  
- Diabetes Mellitus (as comorbidity)  
- Chronic Kidney Disease (CKD)  
- Clinical Trial (General)  
- ISAR‑SAFE Trial  
- HOST‑Exam Trial  
- SMART CHOICE Trial  
- STOP‑DAPT2 Trial  
- TWILIGHT Trial  
- GLOBAL LEADERS Trial  
- PEGASUS‑TIMI 54 Trial  
- TRAP 2P TIMI 50 Trial  
- Network Meta‑analysis  
- Systematic Review  
- Risk Stratification  
- Platelet Activation Pathways  

These terms capture the key concepts, therapies, conditions, and study references related to heart disease discussed in the provided text.

Page 45 Extracted Terms:
- Myocardial infarction (MI)  
- Ischemic stroke  
- Coronary artery disease (CAD)  
- Chronic coronary disease  
- Ischemic heart disease  
- Cardiovascular death  
- Stroke (including intracranial hemorrhage)  
- Intracranial hemorrhage  
- Bleeding (major, moderate, severe)  
- GUSTO moderate or severe bleeding  
- Thienopyridine  
- Vorapaxar  
- Clopidogrel  
- Aspirin  
- Dual antiplatelet therapy (DAPT)  
- Single antiplatelet therapy (SAPT)  
- Percutaneous coronary intervention (PCI)  
- Coronary artery bypass grafting (CABG)  
- Atherothrombotic events  
- Peripheral artery disease  
- Transient ischemic attack (TIA)  
- Revascularization  
- Coronary graft occlusion  
- Saphenous vein graft occlusion  
- Non‑steroidal anti‑inflammatory drugs (NSAIDs)  
- Coxibs  
- Diclofenac  
- Ibuprofen  
- Celecoxib  
- Naproxen  
- Heart failure (HF)  
- Carotid disease  
- Angina (stable and unstable)  
- Major coronary events  
- Vascular death  
- Cardiovascular risk  
- >50 % stenosis  
- History of stroke  
- History of TIA  
- Global Utilization of Streptokinase and Tissue Plasminogen Activator (GUSTO) classification  
- Prasugrel  

Page 46 Extracted Terms:
- Chronic Coronary Disease  
- Stable Coronary Artery Disease (CAD)  
- Acute Coronary Syndrome (ACS)  
- Percutaneous Coronary Intervention (PCI)  
- Coronary Stent  
- Stent Thrombosis  
- Coronary Thrombosis  
- Coronary Revascularization  
- Coronary Atherosclerosis  
- Atrial Fibrillation (AF)  
- Coronary Artery Bypass Grafting (CABG)  
- Myocardial Infarction (MI) / Heart Attack  
- Angina (Stable / Unstable)  
- Major Bleeding  
- Bleeding Risk  
- High Bleeding Risk  
- Non‑vitamin K Oral Anticoagulant (DOAC)  
- Apixaban  
- Rivaroxaban  
- Dabigatran  
- Edoxaban  
- Dual Antiplatelet Therapy (DAPT)  
- Triple Antithrombotic Therapy  
- Aspirin  
- P2Y12 Inhibitor (Clopidogrel, Ticagrelor, etc.)  
- Antithrombotic Regimen  
- Clinical Risk Factors  
- Lesion Complexity  
- Complex Coronary Lesion  
- Cardiovascular Risk Factors  
- Hypertension  
- Hyperlipidemia  
- Family History of Coronary Artery Disease  
- Smoking  
- Nonsteroidal Anti‑Inflammatory Drugs (NSAIDs)  
- Celecoxib  
- Rofecoxib  
- Etoricoxib  
- Lumiracoxib  
- Diclofenac  
- Ibuprofen  
- Naproxen  
- Vitamin K Antagonist (VKA)  
- Stroke  
- Systemic Embolism  
- Coronary Events (e.g., MI, unstable angina, revascularization)  
- Recurrent Coronary Events  
- Coronary Complications  
- Platelet Aggregation  
- Ischemic Risk  
- MACE (Major Adverse Cardiac Events)  

These terms capture the key clinical concepts, interventions, medications, and risk factors discussed in the guideline excerpt.

Page 47 Extracted Terms:
- Chronic Coronary Disease (CCD)  
- Acute Coronary Syndrome (ACS)  
- Atherosclerotic Cardiovascular Disease (ASCVD)  
- Coronary Artery Disease (CAD)  
- Multivessel CAD  
- Myocardial Infarction (MI)  
- Recurrent MI  
- Cardiovascular Death  
- Stroke  
- Ischemic Events  
- All‑cause Death  
- Major Bleeding  
- Major Adverse Cardiovascular Events (MACE)  
- Heart Failure (HF)  
- Left Ventricular Ejection Fraction (LVEF)  
- Preserved LVEF  
- Reduced LVEF (≤40%/≤50%)  
- β‑Blocker Therapy  
- Sustained‑release Metoprolol Succinate  
- Carvedilol  
- Bisoprolol  
- Dual Antiplatelet Therapy (DAPT)  
- Single Antiplatelet Therapy (SAPT)  
- Aspirin  
- Clopidogrel  
- P2Y12 Inhibitors  
- Rivaroxaban (low‑dose)  
- Low‑dose Aspirin  
- Rivaroxaban + Aspirin Combination  
- Periprocedural Antithrombotic Therapy  
- Peripheral Artery Disease (PAD)  
- Chronic Kidney Disease (CKD) / eGFR 15‑59 mL/min/ 2  
- Gastrointestinal Bleeding  
- Proton Pump Inhibitors (PPIs)  
- CYP2C19 Metabolism (clopidogrel activation)  
- AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline  
- COMPASS Trial  
- Efficacy and Safety of Anticoagulation Strategies  

These terms capture the core concepts and conditions related to heart disease discussed in the provided guideline text.

Page 48 Extracted Terms:
- Chronic Coronary Disease (CCD)  
- Heart Failure (HF) with LV systolic dysfunction  
- Left Ventricular Ejection Fraction (LVEF)  
- LV systolic dysfunction (LVEF ≤ 40%)  
- Mid‑range LVEF (40 – 49%)  
- Major Adverse Cardiovascular Events (MACE)  
- Cardiovascular death  
- Myocardial Infarction (MI) – previous and new  
- Ischemic heart disease (stable ischemic heart disease)  
- Stable angina  
- Percutaneous coronary intervention (PCI)  
- Coronary Artery Disease (CAD)  
- Beta‑blocker therapy  
  - Bisoprolol (CIBIS‑II)  
  - Carvedilol (COPERNICUS)  
  - Metoprolol succinate (MERIT‑HF)  
- Renin‑Angiotensin‑Aldosterone Inhibitors (RAASi)  
  - Angiotensin‑converting enzyme inhibitors (ACEi)  
  - Angiotensin‑II receptor blockers (ARBs)  
  - ACE‑intolerant indications  
- Hypertension  
- Diabetes mellitus  
- Chronic kidney disease (CKD)  
- Clinical trial and registry acronyms  
  - REBOOT‑CNIC  
  - REDUCE‑SWEDEHEART  
  - BETAMI  
  - DANBLOCK  
  - REACH (Reduction of Atherothrombosis for Continued Health)  
  - CHARISMA (Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance)  
- Antithrombotic therapy  
- Lipid‑lowering (statin) therapy  
- Quality of life (QOL) outcomes  
- Observational studies vs randomized controlled trials (RCTs)  
- Long‑term beta‑blocker use (> 1 year)  
- Clinical benefits and risks (fatigue, depression, drug–drug interactions)  
- Cardiovascular morbidity and mortality outcomes at 30 days, 3‑year follow‑up  

These terms capture the key heart‑disease concepts discussed in the guideline excerpt.

Page 49 Extracted Terms:
- Chronic Coronary Disease (CCD)  
- Heart Failure (HF)  
- Left Ventricular Ejection Fraction (LVEF)  
- Major Adverse Cardiovascular Events (MACE)  
- Renin–Angiotensin–Aldosterone System Inhibitors (RAASi)  
- Angiotensin‑Converting Enzyme Inhibitors (ACEi)  
- Angiotensin II Receptor Blockers (ARBs)  
- Hypertension  
- Diabetes Mellitus  
- Chronic Kidney Disease (CKD)  
- Blood Pressure (BP)  
- Lipid Management  
- Colchicine  
- Atherothrombotic Cardiovascular Disease (ASCVD)  
- Perindopril  
- Ramipril  
- Trandolapril  
- Quinapril  
- Amlodipine  
- Enalapril  
- COLCOT Trial  
- LoDoCo Trial  
- LoDoCo2 Trial  
- HOPE Trial  
- EUROPA Trial  
- PEACE Trial  
- CAMELOT Trial  
- IMAGINE Trial  
- AHA/ACC Chronic Coronary Disease Guideline  
- HFSA Heart Failure Guideline

Page 50 Extracted Terms:
- Chronic Coronary Disease  
- Atherosclerotic Cardiovascular Disease (ASCVD)  
- Acute Coronary Syndrome (ACS)  
- Myocardial Infarction (MI)  
- Coronary Artery Disease (CAD)  
- Ischemic Heart Disease  
- Heart Failure (HF)  
- Angina  
- Coronary Revascularization  
- Ischemic Stroke  
- Major Adverse Cardiovascular Events (MACE)  
- Cardiovascular Death  
- Cardiovascular Morbidity  
- Cardiovascular Mortality  
- Cardiovascular Outcomes  
- Vulnerable Atherosclerotic Plaques  
- Colchicine Therapy (colchicine)  
- Influenza Vaccination (as a preventive measure for cardiovascular risk)  
- COVID‑19 Vaccination (as a preventive measure for cardiovascular risk)  
- Pneumococcal Polysaccharide Vaccination (as a preventive measure for cardiovascular risk)

Page 51 Extracted Terms:
**Key heart‑disease related terms extracted from the text**

- Chronic Coronary Disease (CCD)  
- Angina pectoris / angina  
- Anti‑anginal therapy  
- Beta blocker  
- Calcium‑channel blocker (CCB)  
- Dihydropyridine CCB (e.g., amlodipine, nifedipine)  
- Non‑dihydropyridine CCB (verapamil, diltiazem)  
- Long‑acting nitrate (e.g., isosorbide dinitrate, nitroglycerin)  
- Sublingual nitroglycerin  
- Nitroglycerin spray  
- Ranolazine  
- Ivabradine  
- Left ventricular (LV) dysfunction / LV function  
- Myocardial oxygen demand  
- Myocardial arterial blood supply  
- Late sodium current (mechanism of ranolazine)  
- Myocardial ischemia  
- Myocardial infarction (MI)  
- Transient ischemic attack (TIA)  
- Stroke  
- Cardiovascular risk (high or very high)  
- Cardiac arrest  
- Mortality (all‑cause death)  
- Pneumococcal polysaccharide vaccine (PPV)  
- Influenza vaccine  
- PPSV23  
- PCV13 (pneumococcal conjugate vaccine)  
- Combined vaccination (PPV + influenza)  
- Exercise duration / exercise tolerance  
- Nitroglycerin consumption  
- Bradycardia  

These terms capture the diseases, therapeutic agents, physiological concepts, and outcome measures that are central to the clinical guidelines discussed.

Page 52 Extracted Terms:
- Chronic Coronary Disease (CCD)  
- Angina  
- Stable Angina  
- Refractory Angina  
- Ischemic Heart Disease  
- Coronary Revascularization  
- Enhanced External Counterpulsation (EECP)  
- Transmyocardial Laser Revascularization (TLR)  
- Ranolazine  
- Ivabradine  
- Amlodipine  
- Atenolol  
- Nitroglycerin  
- Short‑acting Nitrates  
- Nitroglycerin Spray  
- Sublingual Nitroglycerin  
- Cardiovascular Death  
- Myocardial Infarction (MI)  
- Exercise Capacity / Exercise Time  
- Anginal Episodes  
- Nitroglycerin Consumption  
- Resting Heart Rate  
- Disodium EDTA (Chelation Therapy)  
- AHA/ACC/ACCP/ASPC/NLA/PCNA Chronic Coronary Disease Guideline  
- Clinical Statement / Guideline Recommendation  

Page 53 Extracted Terms:
- Chronic Coronary Disease (CCD)  
- Coronary Artery Disease (CAD)  
- Myocardial Infarction (MI)  
- Angina  
- Coronary artery stenoses  
- Revascularization  
- Coronary Artery Bypass Grafting (CABG)  
- Percutaneous Coronary Intervention (PCI)  
- Fractional Flow Reserve (FFR)  
- Instantaneous Wave‑Free Ratio (iFR)  
- Left Ventricular (LV) dysfunction  
- Left Ventricular Ejection Fraction (LVEF)  
- Cardiovascular events  
- Cardiovascular death  
- Urgent revascularization  
- Coronary angiography  
- Heart Team approach  
- Coronary artery revascularization  
- Cardiac death  
- Non‑fatal events  
- Severe LV dysfunction (LVEF ≤ 35 %)  
- Complex three‑vessel disease  
- Diabetes (comorbidity)  
- Renal dysfunction (comorbidity)  
- Atherosclerotic burden  
- Guideline‑Directed Medical Therapy (GDMT)  
- Quality of Life (QOL)  
- Meta‑analyses  
- Clinical trials (e.g., TACT, TACT2)  
- Cardiovascular disease (general term)

Page 54 Extracted Terms:
- Chronic Coronary Disease (CCD)  
- Left ventricular dysfunction  
- Left ventricular ejection fraction (LVEF)  
- LVEF ≤ 35 %  
- Left main coronary disease  
- Coronary artery bypass grafting (CABG)  
- Percutaneous coronary intervention (PCI)  
- Glucose‑directed medical therapy (GDMT) / guideline‑directed medical therapy  
- Medical therapy alone  
- Ischemic cardiomyopathy  
- Heart failure (HF) secondary to coronary disease  
- Non‑fatal myocardial infarction (MI)  
- Unstable angina  
- Angina (baseline angina frequency)  
- Seattle Angina Questionnaire (SAQ)  
- Fractional Flow Reserve (FFR)  
- FFR‑guided PCI  
- STICH trial  
- ISCHEMIA trial  
- COURAGE trial  
- ORBITA trial  
- REVIVED‑BCIS 2 trial  
- AHA/ACC/ACCP/ASPC/NLA/PCNA chronic coronary disease guideline  
- Revascularization (surgical or catheter‑based)  
- Surgical revascularization  
- Catheter‑based revascularization  
- Ischemia burden  
- Mortality benefit of CABG over GDMT  
- MACE (major adverse cardiovascular events)  
- QALYs (quality‑adjusted life years)  
- Incremental cost‑effectiveness ratio (ICER)  
- Lifetime costs  
- Lifetime QALYs  
- Crossover rate in trials  
- Angiographic complexity  
- Optimal medical therapy (OMT)  
- Clinical events (non‑fatal MI, unstable angina, urgent revascularization)

Page 55 Extracted Terms:
- Chronic Coronary Disease (CCD)  
- Revascularization (including CABG and PCI)  
- Coronary artery bypass grafting (CABG)  
- Percutaneous coronary intervention (PCI)  
- Coronary artery disease (CAD)  
- Left main disease / left main CAD  
- Multi‑vessel disease  
- Severe coronary stenosis (≥70 %)  
- 3‑vessel disease  
- 2‑vessel disease with proximal left anterior descending artery  
- Cardiovascular death  
- Myocardial infarction (MI)  
  - Spontaneous MI (type 1)  
  - Demand‑induced MI (type 2)  
  - Procedural MI (type 4a)  
  - Stent‑related MI (type 4b)  
  - Restenosis‑related MI (type 4c)  
- Unstable angina  
- Procedural type 4a MI  
- Procedural type 4b MI  
- Procedural type 4c MI  
- Clinical events (cardiac death, MI, etc.)  
- ISCHEMIA trial  
- FAME‑2 trial  
- FFR‑guided PCI (fractional flow reserve ≤ 0.8)  
- iFR‑guided PCI (instantaneous wave‑free ratio > 0.89)  
- Non‑hyperemic pressure ratios  
- DES (drug‑eluting stents)  
- Angiography‑guided PCI  
- Angiographic severity (≥50 %)  
- MACE (major adverse cardiovascular events)  
- Acute versus chronic ischemia  
- ejection fraction  
- High‑risk clinical scenarios (comorbid conditions, social factors)  
- Heart Team (interventional cardiology, cardiac surgery, cardiovascular specialists)  
- GDMT (guideline‑directed medical therapy)  
- QALY (quality‑adjusted life year)  
- Incremental cost‑effectiveness ratio (ICER)  
- Economic evaluation of PCI vs. medical therapy  
- Network meta‑analysis  
- Survival advantage of PCI over medical therapy in left‑main CAD  
- Survival advantage of CABG over medical therapy in left‑main CAD  
- Stability of chronic coronary syndromes  
- Redirection of care to interventional strategies  
- Cardiovascular specialists  

*(All terms are extracted from the guideline text and pertain to diagnosis, treatment, outcomes, and health‑system decision‑making in heart disease.)*

Page 56 Extracted Terms:
- Chronic Coronary Disease (CCD)  
- Coronary Artery Bypass Grafting (CABG)  
- Percutaneous Coronary Intervention (PCI)  
- Left main coronary artery disease  
- High‑complexity coronary artery disease (CAD)  
- SYNTAX score (≥ 33 cutoff)  
- Multivessel coronary artery disease  
- Major Adverse Cardiovascular Events (MACE)  
- Survival benefit  
- Mortality (cardiac and all‑cause)  
- Ischemic myocardium  
- Ischemic insult  
- Spontaneous myocardial infarction (MI)  
- Repeat revascularization  
- Diabetic coronary artery disease  
- Left anterior descending artery (LAD) involvement  
- Left internal mammary artery (LIMA) graft  
- Heart Team decision making  
- Shared decision‐making process  
- Physical Component Summary (PCS)  
- Mental Component Summary (MCS)  
- Left ventricular (LV) dysfunction  
- Non‑viable myocardium  
- Frailty / immobility  
- Severe lung disease  
- Subclinical coronary anatomy complexity  
- De novo coronary lesions  
- Coronary artery protection strategy  
- Surgical risk stratification  
- Percutaneous revascularization registry data  
- Retrospective outcomes (10‑year follow‑up)  
- Randomized controlled trials (RCTs)  
- Pooled individual patient data analysis  
- Clinical evidence modifiers  
- Coronary artery disease risk modifiers  
- Revascularization strategy recommendations (CABG vs PCI)  
- Chronic stable ischemic heart disease guideline citations  
- AHA/ACC/ACCP/ASPC/NLA/PCNA Chronic Coronary Disease Guideline (2023)


Page 57 Extracted Terms:
- Chronic Coronary Disease (CCD)  
- Coronary Artery Disease (CAD)  
- Spontaneous Coronary Artery Dissection (SCAD)  
- Percutaneous Coronary Intervention (PCI)  
- Coronary Artery Bypass Graft (CABG)  
- Left Main Stenosis  
- Left Anterior Descending Artery (LAD)  
- Multivessel Disease  
- Triple‑Vessel Disease  
- Myocardial Infarction (MI)  
- Stroke  
- Dual Antiplatelet Therapy (DAPT)  
- Beta‑Blocker Therapy  
- Renin‑Angiotensin‑Aldosterone System Inhibitors (RAAS inhibitors)  
- Coronary Revascularization  
- Coronary Pathology  
- Ischemia  
- Ischemia with No Obstructive Coronary Artery Disease (INOCA)  
- Cardiovascular Disease (CVD)  
- Atherosclerotic Cardiovascular Disease (ASCVD)  
- Atherosclerosis  
- Coronary Intervention  
- Heart Failure  
- Left Ventricular Dysfunction  
- Surgical Ineligibility  
- Composite Primary Endpoint (Death, MI, Stroke)  
- FREEDOM Trial  
- EXCEL Trial  
- Meta‑analysis  
- Hazard Ratio  
- Confidence Interval  
- Coronary Stenting  
- Coronary Angiography  
- Coronary Anatomy  
- Angioplasty  
- Cardiac Rehabilitation (CR)  
- Vascular Pathology

Page 58 Extracted Terms:
- Spontaneous coronary artery dissection (SCAD)  
- Coronary artery disease (CAD)  
- Nonobstructive coronary arteries  
- Ischemia with nonobstructive coronary arteries (INOCA)  
- Angina  
- Quality of life (QOL)  
- Fibromuscular dysplasia  
- Cerebral aneurysm  
- Aortic aneurysm  
- Peripheral aneurysm  
- Aortic dissection  
- Peripheral dissection  
- Myocardial infarction  
- Stroke (cerebral ischemia)  
- Transient ischemic attack (TIA)  
- Hypertension (high blood pressure)  
- Familial hypercholesterolemia (FH)  
- Statin therapy  
- Beta‑blocker therapy  
- Dual antiplatelet therapy (DAPT)  
- Antiplatelet therapy  
- Oral anticoagulation  
- Coronary physiology testing  
- Recurrent SCAD  
- Vascular abnormalities (extracoronary)  
- Connective tissue disorders  
- Ehlers‑Danlos syndrome (vascular type)  
- Marfan syndrome  
- Loeys‑Dietz syndrome  
- Pulmonary hypertension (relevant for cardiovascular risk)  
- Coronary vasculopathy  
- Coronary arteriopathy  
- Coronary artery tortuosity  
- Cardiac valve abnormality  
- Aortic valve disease  
- Heart failure (as a potential outcome)  
- Cardiac remodeling (associated with ischemia)

Page 59 Extracted Terms:
- Coronary artery disease (CAD)  
- Nonobstructive coronary artery disease (nonobstructive CAD)  
- Ischemia without obstructive coronary artery disease (INOCA)  
- Myocardial ischemia  
- Coronary vasomotor dysfunction  
- Coronary microvascular dysfunction  
- Microvascular angina  
- Vasospastic angina  
- Coronary microvascular resistance  
- Index of microcirculatory resistance (IMR)  
- Fractional flow reserve (FFR)  
- Coronary flow reserve (CFR)  
- Coronary computed tomography angiography (CTA)  
- Coronary angiography  
- Acetylcholine testing  
- Calcium channel blockers  
- Nitrate‑responsive angina  
- Transient ischemic electrocardiographic changes  
- ST‑segment elevation  
- ST‑segment depression  
- Negative U waves  
- Coronary artery spasm  
- Provocative stimuli (acetylcholine, ergot)  
- Hyperventilation  
- Exercise tolerance / diurnal variation in exercise tolerance  
- Seattle Angina Questionnaire  
- EuroQoL (EQ‑5D‑5L)  
- Major adverse cardiovascular events (MACE)  
- Invasive coronary physiology testing  
- CorMicA trial (Coronary Microvascular Angina trial)  
- COVADIS diagnostic criteria (Coronary Vasomotion Disorders International Study Group)  
- Coronary slow flow phenomenon  
- TIMI frame count  
- Epicardial coronary obstruction  
- Coronary microvascular resistance indices  
- Electrocardiogram (ECG)

Page 60 Extracted Terms:
**Key Heart‑Disease Terms Extracted**

- Coronary artery disease (CAD)  
- Chronic coronary disease (CCD)  
- Heart failure (HF)  
- Heart failure with preserved ejection fraction (HFpEF)  
- Heart failure with reduced ejection fraction (HFrEF)  
- Valvular heart disease  
- Revascularization  
- Coronary microvascular dysfunction (CMD)  
- Microvascular angina (MVA)  
- Vasospastic angina (VSA)  
- Epicardial coronary artery spasm  
- Coronary flow reserve (CFR)  
- Index of microvascular resistance (IMR)  
- Fractional flow reserve (FFR)  
- Angina  
- Acetylcholine testing (coronary function testing)  
- Epicardial coronary diameter reduction  
- Coronary vasorelaxation  
- Coronary vasospasm  
- Coronary vasodilator capacity  
- Non‑obstructive CAD  
- Obstructive CAD (≥ 50 % diameter stenosis, FFR ≤ 0.80)  
- Microvascular resistance (high)  
- Coronary endothelial function  
- Coronary hemodynamics  
- Coronary artery diameter  
- Cardiovascular events prevention (therapeutic focus)  

(The above list focuses on clinical entities, diagnostic measures, and disease processes relevant to the guideline text.)

Page 61 Extracted Terms:
**Key terms related to heart disease**

- Chronic Coronary Disease (CCD)  
- Coronary Artery Disease (CAD)  
- Valvular heart disease  
- Severe aortic stenosis  
- Percutaneous coronary intervention (PCI)  
- Transcatheter aortic valve implantation (TAVI)  
- Dual antiplatelet therapy (DAPT)  
- Major adverse cardiovascular events (MACE)  
- Cardiovascular events  
- Cardiovascular morbidity  
- Quality‑adjusted life years (QALYs)  
- Hyperlipidemia  
- Low‑density lipoprotein cholesterol (LDL‑C)  
- Lipoprotein(a) (Lp(a))  
- Familial hypercholesterolemia (FH)  
- Statin therapy  
- Lipid screening (family members)  
- Hypertension  
- Diabetes mellitus  
- Obesity / Metabolic syndrome  
- Smoking / Vaping  
- Recreational substance use (cocaine, marijuana)  
- Unhealthy diet  
- Physical inactivity  
- Traditional cardiovascular risk factors  
- Non‑traditional risk factors  
- Human immunodeficiency virus (HIV)  
- Antiretroviral therapy (ART)  
- Systemic inflammatory disorders (IBD, SLE, RA, gout, psoriatic arthritis, ankylosing spondylitis)  
- Vasculitides  
- Pregnancy‑related complications (IUGR, hypertensive disorders of pregnancy, gestational diabetes)  
- Coronary anomalies  
- Kawasaki disease  
- Myocardial bridging  
- Secondary prevention strategies  
- Revascularization guidelines  
- Blood pressure management  
- Weight management  
- Diabetes management (SGLT‑2 inhibitors, GLP‑1 receptor agonists)  
- Nutrition and supplements  
- Physical activity  
- Tobacco products  
- Medication adherence  
- Health information technology tools  
- Social determinants of health  

These terms capture the spectrum of conditions, interventions, risk factors, and prevention strategies associated with heart disease as described in the guideline text.

Page 62 Extracted Terms:
- Chronic Coronary Disease (CCD)  
- Cardiovascular Disease (CVD)  
- Heart disease  
- Coronary artery disease  
- Coronary artery anomalies  
- Coronary vasospasm  
- Coronary artery aneurysm  
- Coronary artery stenosis  
- Coronary artery thrombosis  
- Coronary artery fistula  
- Kawasaki disease (coronary sequelae)  
- Myocardial bridging  
- Cardiac toxicity  
- Cardio‑oncology  
- Antiplatelet therapy  
- Antithrombotic therapy  
- Thromboprophylaxis  
- Apixaban  
- Rivaroxaban  
- Low‑molecular‑weight heparin  
- Beta‑adrenergic blocking agents  
- Exercise‑induced ischemia  
- Sudden cardiac death  
- Interarterial course of coronary artery  
- Anomalous left coronary artery from the pulmonary artery  
- Anomalous origin of the coronary artery from the opposite sinus of Valsalva  
- Surgical repair of coronary anomalies (e.g., translocation to the aortic root)  
- Surgical correction of interarterial coronary anomaly  
- Coronary vasospasm treatment  
- Myocardial ischemia  
- Cardiac dysfunction  
- Multidisciplinary cardio‑oncology team

Page 63 Extracted Terms:
- Chronic coronary disease (CCD)  
- Cardiovascular complications  
- Ischemic cardiovascular events  
- Adverse maternal and fetal outcomes  
- Adverse cardiac events  
- Maternal cardiac death  
- Cardiac arrest  
- Sustained arrhythmia requiring treatment  
- Left‑sided heart failure (HF) / pulmonary edema  
- Right‑sided heart failure  
- Stroke  
- Transient ischemic attack (TIA)  
- Cardiac thromboembolism  
- Myocardial infarction (MI)  
- Vascular dissection  
- Coronary artery disease (CAD)  
- Ventricular dysfunction  
- Mechanical valve  
- High‑risk left‑sided valve disease  
- Left‑ventricular outflow tract (LVOT) obstruction  
- Pulmonary hypertension  
- High‑risk aortopathy  
- NYHA functional class III‑IV  
- Cyanosis  
- Late pregnancy assessment  
- Cardiac intervention (e.g., surgery, catheterization)  
- CARPREG II risk prediction model / predictors  
- CARPREG II risk score  
- Pre‑eclampsia  
- Pre‑term delivery  
- Small for gestational age infant  
- Cardio‑obstetric care team  
- Cardio‑obstetrics  
- Statin use during pregnancy  
- Angiotensin‑converting enzyme (ACE) inhibitors  
- Angiotensin‑II receptor blockers (ARBs)  
- Direct renin inhibitors  
- Angiotensin receptor‑neprilysin inhibitors  
- Aldosterone antagonists  
- Estrogen‑only hormone regimens  
- Combined estrogen‑and‑progestin hormone regimens  
- Venous thromboembolism (VTE)  
- Systemic postmenopausal hormone therapy  
- Postmenopausal hormone therapy  
- MACE (major adverse cardiovascular events)  
- Multidisciplinary cardio‑obstetric care  
- Pregnancy outcomes in women with heart disease (CARPREG)  
- Cardiovascular risk stratification  

These terms capture the key heart‑disease–focused concepts, conditions, therapies, and risk factors discussed in the guideline excerpt.

Page 64 Extracted Terms:
**Key heart‑disease related terms extracted from the guideline text**

- Arrhythmias  
- Metoprolol  
- Propranolol  
- Digoxin  
- Lidocaine  
- Verapamil  
- Diltiazem  
- Procainamide  
- Sotalol  
- Flecainide  
- Propafenone  
- Amiodarone  
- Heart failure  
- Carvedilol  
- Furosemide  
- Bumetanide  
- Dopamine  
- Dobutamine  
- Norepinephrine  
- Hydralazine  
- Nitroglycerin  
- Isosorbide dinitrate  
- Torsemide  
- Metolazone  
- Warfarin  
- Unfractionated heparin  
- Enoxaparin  
- Fondaparinux  
- Argatroban  
- Bivalirudin  
- Aspirin (low dose)  
- Clopidogrel  
- Prasugrel  
- Ticagrelor  
- Alteplase  
- Streptokinase  
- Labetalol  
- Nifedipine  
- α‑Methyldopa  
- Nitroprusside  
- Amlodipine  
- Hydrochlorothiazide  
- Clonidine  
- Atenolol  
- ACE‑inhibitor class (e.g., captopril, benazepril, enalapril)  
- ARB class (e.g., losartan, valsartan)  
- Aldosterone antagonists  
- Statin class  
- Direct oral anticoagulants (DOACs)  
- Endothelin‑receptor antagonists (ERAs)  
- Cardio‑obstetrics team / multidisciplinary cardio‑obstetrics  
- Maternal‑fetal medicine / obstetric cardiology  
- Pregnancy  
- Lactation  
- Cardiovascular medication safety (pregnancy, lactation)  
- Pharmacokinetics in pregnancy (absorption, volume of distribution, protein binding, clearance, uteroplacental flow, fetal metabolism)  
- Cardiovascular risk factors  
- Cardiovascular complications of pregnancy  
- Monitoring and management of cardiovascular disease during labor, delivery, and postpartum.

Page 65 Extracted Terms:
**Key Terms Related to Heart Disease**

- Chronic Coronary Disease  
- Cardio‑Obstetrics (team‑based cardio‑obstetrics model of care)  
- Cardiac Disease  
- Cardiovascular Disease (CVD)  
- Congenital Heart Disease  
- CARPREG II (Cardiac Disease in Pregnancy study)  
- ZAHARA (Zwangerschap bij Aangeboren HARtAfwijking – Pregnancy in Women With Congenital Heart Disease) study  
- mWHO (modified World Health Organization) cardiac risk classification  
- Statin exposure (as a medication affecting cardiovascular risk)  

These terms capture the major heart‑disease concepts, conditions, and research frameworks mentioned in the provided text.

Page 66 Extracted Terms:
- Chronic Coronary Disease (CCD)  
- Coronary Artery Disease (CAD)  
- Myocardial Infarction (MI)  
- Acute MI  
- Coronary revascularization  
- Coronary angiography  
- Coronary artery bypass grafting (CABG)  
- Drug‑prescription antiplatelet therapy (DAPT)  
- Antithrombotic agents  
- Antiplatelet agents  
- ACE inhibitors  
- Angiotensin‑II receptor blockers (ARBs)  
- Direct renin inhibitors  
- Angiotensin‑receptor neprilysin inhibitors (ARNIs)  
- Aldosterone antagonists  
- Statins  
- Lipoprotein apheresis  
- Hormone therapy (estrogen, estrogen‑progesterin, oral contraceptives, hormonal contraceptives)  
- Venous thromboembolism (VTE)  
- Stroke  
- Angina pectoris  
- Cardiovascular death  
- Angiographic progression of disease  
- Saphenous vein grafts  
- Transwomen cardiovascular risk  
- Older‑adult heart disease risk  
- Geriatric 5‑Ms (related to cardiovascular outcomes: Mentation, Mobility, Medications, Multicomplexity)

Page 67 Extracted Terms:
- Chronic Coronary Disease (CCD)  
- Coronary Artery Disease (CAD)  
- Ischemia  
- Atherosclerosis  
- Revascularization  
- Percutaneous Coronary Intervention (PCI)  
- Coronary Artery Bypass Grafting (CABG)  
- Contrast‑induced Acute Kidney Injury (AKI)  
- Contrast‑induced nephropathy  
- Statins (high‑dose statins)  
- Antiretroviral Therapy (ART)  
- Lipid profile / dyslipidemia  
- Cardiovascular events (CVE)  
- Glucocorticoids (high‑dose)  
- Disease‑modifying anti‑rheumatic drugs (DMARDs)  
- Biologics / immune‑modulating therapies  
- Inflammation (and inflammatory markers)  
- Hydration (pre‑contrast)  
- Iodinated contrast agent  
- Radial access (for PCI)  
- Bicarbonate  
- N‑acetyl‑L‑cysteine (NAC)  
- Normal saline (for AKI prevention)  

These terms represent key concepts related to heart disease that appear in the provided guideline excerpt.

Page 68 Extracted Terms:
- Chronic Coronary Disease  
- Coronary Artery Disease (CAD)  
- Myocardial Infarction (MI)  
- Atherosclerosis  
- Atherosclerotic Cardiovascular Disease (ASCVD)  
- Cardiovascular Disease (CVD)  
- Cardiovascular risk  
- Lipid profile  
- Low‑density lipoprotein cholesterol (LDL‑C)  
- Low‑density lipoprotein (LDL)  
- High‑density lipoprotein cholesterol (HDL‑C)  
- High‑density lipoprotein (HDL)  
- Hypertriglyceridemia  
- Cholesterol management  
- Lipid levels  
- LDL‑C reduction  
- Cardiovascular risk profile  
- Cardiovascular events  
- Cardiovascular health risk discussion  

Page 69 Extracted Terms:
**Heart‑disease related terms extracted from the guideline text**

- Chronic Coronary Disease  
- Cardiac Allograft Vasculopathy  
- Heart Transplant  
- Major Adverse Cardiovascular Events (MACE)  
- Secondary prevention  
- Statins (e.g., simvastatin, pravastatin, simvastatin)  
- Aspirin  
- Revascularization  
- Coronary angiography  
- Intravascular ultrasound  
- High‑intensity interval training  
- Percutaneous coronary intervention (PCI)  
- Drug‑eluting stents (DES)  
- Coronary artery bypass grafting (CABG)  
- Retransplantation  
- Mycophenolate mofetil  
- Azathioprine  
- Calcineurin inhibitor  
- Proliferation‑signal inhibitor  
- Grade ≥ 2R rejection  
- Lipid management  
- Blood‑pressure management  
- Sodium‑glucose cotransporter‑2 inhibitors (SGLT2i)  
- Glucagon‑like peptide‑1 receptor agonists (GLP‑1 RA)  
- Cardiovascular events  
- Cardiovascular risk factors  
- Inflammation (as a cardiovascular risk factor)  
- Rheumatoid arthritis (inflammatory cardiovascular risk)  
- Methotrexate (cardiovascular risk modifier)  
- Biologic disease‑modifying antirheumatic drugs  
- Janus kinase inhibitors  
- Tumor necrosis factor inhibitors  
- Immunomodulators  
- Glucocorticoids  
- Prednisone  
- Triglyceride levels ≥ 500 mg/dL (cardiovascular risk)  
- Protease inhibitors (drug interaction impacting cardiovascular drugs)  
- Antiplatelet drugs (e.g., ticagrelor)  


These terms capture the core concepts, interventions, and risk factors related to heart disease as discussed in the provided guideline excerpt.

Page 70 Extracted Terms:
- Chronic Coronary Disease  
- Cardiac Allograft Vasculopathy  
- Cardiac Allograft Vasculopathy Progression  
- Coronary Artery Disease  
- Atherosclerotic Plaque Volume  
- Plaque Index  
- Intravascular Ultrasound  
- Statin Therapy  
- Low‑Intensity Statin  
- Moderate/High‑Intensity Statin  
- Aspirin Therapy  
- Revascularization  
- Percutaneous Coronary Intervention (PCI)  
- Coronary Artery Bypass Grafting (CABG)  
- Drug‑Eluting Stent (DES)  
- Everolimus‑Eluting Stents  
- In‑Stent Restenosis  
- Fractional Flow Reserve (FFR)  
- Index of Microcirculatory Resistance (IMR)  
- Immunosuppressive Drugs (Cyclosporine, Tacrolimus, Everolimus, Sirolimus)  
- Atorvastatin  
- Rosuvastatin  
- Pravastatin  
- Fluvastatin  
- Simvastatin  
- Lovastatin  
- Pitavastatin  
- Area Under the Curve (AUC)  
- Drug‑Drug Interaction  
- Mortality  
- Myocardial Infarction (MI)  
- Heart Failure (HF) Hospitalization  
- All‑Cause Death  
- Cardiac Allograft Vasculopathy‑Related Events  
- Graft Dysfunction  
- Discrete Lesions  
- Second‑Generation DES  
- Early (<2 Years) vs Late (>2 Years) Statin Initiation  
- Early (<1 Year) vs Late (>1 Year) Aspirin Initiation

Page 71 Extracted Terms:
**Key heart‑disease related terms extracted from the guideline text**

- Chronic Coronary Disease (CCD)  
- Acute Coronary Syndrome (ACS)  
- Coronary revascularization  
- Telehealth programs  
- Lifestyle interventions (e.g., Hartcoach, Proactive Heart, MoodCare)  
- Cardiovascular risk factors  
- Guideline‑Directed Medical Therapy (GDMT)  
- Coronary Computed Tomography Angiography (CTA)  
- Stress testing (with or without imaging)  
- Left ventricular (LV) function assessment  
- Invasive coronary angiography  
- Major adverse cardiovascular events (MACE)  
- 12‑lead electrocardiogram (ECG)  
- Angina  
- Functional capacity  
- Cardiac rehabilitation (CR)  
- ISCHEMIA trial (stable CAD, ischemia)  
- Stable coronary artery disease (CAD)  
- Ischemia  
- Clinical follow‑up plan and testing  
- Risk‑factor modification  
- Shared decision‑making (among cardiology, primary, and specialty teams)  
- Patient education and social determinants of health (contextual factors influencing care)

Page 72 Extracted Terms:
- Chronic Coronary Disease (CCD)  
- Coronary Artery Disease (CAD)  
- Cardiovascular Disease (CVD)  
- Left Ventricular Function  
- Left Ventricular Ejection Fraction (LVEF)  
- Major Adverse Cardiovascular Events (MACE)  
- Anginal Symptoms  
- Silent Ischemia  
- Cardiovascular Death  
- Myocardial Infarction (MI)  
- Percutaneous Coronary Intervention (PCI)  
- Coronary Artery Bypass Grafting (CABG)  
- Invasive Coronary Angiography  
- Revascularization  
- Routine Follow‑up Coronary Angiography  
- Routine Functional Stress Testing  
- Exercise ECG  
- Nuclear Myocardial Perfusion Imaging  
- Stress Echocardiography  
- ISCHEMIA Trial  
- Unstable Angina  
- Composite Endpoint (Death, MI, Hospitalization)  
- Post‑PCI  
- Diabetes (in the context of cardiac care)  
- High‑Risk Patients  
- Nonischemic Intermediate Lesions  
- Cost‑Related Medication Non‑Adherence  
- Out‑of‑Pocket Costs  
- SGLT2 Inhibitors  
- Lipid Management  
- High‑Cost Therapies  
- Shared Decision‑Making  
- Cost‑Effectiveness  



Page 73 Extracted Terms:
- Chronic Coronary Disease (CCD)  
- Major Adverse Cardiovascular Events (MACE)  
- Noninvasive imaging  
- Calcified plaque burden  
- Non‑calcified plaque burden  
- Atherosclerosis  
- Risk scores (comprehensive, contemporary)  
- Patient demographics  
- Social determinants of health  
- Patient‑reported measures  
- Patient‑centered outcomes  
- Shared decision‑making  
- Decision aids  
- Guideline‑Directed Medical Therapy (GDMT)  
- Sequencing GDMT  
- Antiplatelet regimen  
- Antithrombotic strategy  
- Atrial fibrillation  
- Refractory angina  
- Neuro‑modulation  
- Thoracic spinal‑cord stimulation  
- Therapeutic angiogenesis  
- Cell/gene therapies  
- Coronary sinus occlusion  
- Shockwave therapy  
- Hybrid cardiac rehabilitation (CR)  
- Home‑based cardiac rehabilitation  
- Mental health (depression)  
- E‑cigarette use  
- GLP‑1 receptor agonists  
- SGLT2 inhibitors  
- Clinical estimation of symptoms  
- Cost‑saving approaches (mail order pharmacy, patient assistance programs)  
- Artificial intelligence  
- Text messaging  
- Wearable technology  
- Genomics  
- Proteomics  
- Spontaneous coronary artery dissection (SCAD)  
- Vasculopathy screening  
- Climate‑change‑related cardiovascular impact  
- Percutaneous coronary intervention (PCI)  
- Myocardial infarction (MI)  
- Cardiovascular prevention measures  

Page 74 Extracted Terms:
- Chronic Coronary Disease (CCD)  
- Cardiovascular events  
- Cardiovascular outcomes  
- Preventive strategies (e.g., indoor air purifiers, N95 masks)  
- Wildfire smoke exposure  
- Extreme heat exposure  
- Social Determinants of Health (SDOH)  
- Electronic health records (EHR)  
- Patient out‑of‑pocket costs  
- Guideline‑Directed Medical Therapy (GDMT)  
- Hemodialysis patients with coronary disease  
- Guideline implementation in clinical practice  
- Clinical practice guidelines (ACC/AHA/ACCP/ASPC/NLA/PCNA)  
- Atherosclerotic cardiovascular disease (implicit in chronic coronary disease)

Page 75 Extracted Terms:
- Chronic Coronary Disease  
- Stable Ischemic Heart Disease  
- Unstable Angina  
- Non‑ST‑elevation Myocardial Infarction (NSTEMI)  
- ST‑elevation Myocardial Infarction (STEMI)  
- Coronary Artery Revascularization  
- Coronary Artery Disease  
- Chest Pain Evaluation  
- Primary Prevention of Cardiovascular Disease  
- Secondary Prevention of Atherosclerotic Vascular Disease  
- Management of Blood Cholesterol  
- Dual Antiplatelet Therapy Duration  
- Ventricular Arrhythmias  
- Sudden Cardiac Death Prevention  
- Hypertension (High Blood Pressure)  
- Atrial Fibrillation Management  
- Valvular Heart Disease  
- Cardiovascular Disease  
- Myocardial Infarction  
- Angina  
- Chronic Coronary Disease Guideline

Page 76 Extracted Terms:
- Heart disease  
- Coronary artery disease  
- Acute coronary syndrome  
- Stable ischemic heart disease  
- Heart failure  
- Hypertension  
- Atherosclerotic cardiovascular disease (ASCVD)  
- Atrial fibrillation  
- Venous thromboembolism  
- Percutaneous coronary intervention (PCI)  
- Cardiac rehabilitation  
- Secondary prevention  
- Spontaneous coronary artery dissection  
- Cardio‑oncology drug interactions  
- Statins  
- Novel cardiovascular risk‑reduction therapies  
- Hypertriglyceridemia  
- Tobacco cessation treatment  
- Cardiac stress imaging  
- Left ventricular function  
- Ischemic burden  
- Ischemia  
- Myocardial scar  
- Diabetes mellitus type 2 (in relation to coronary disease)  
- Cardiovascular health (Life’s Essential 8)  
- Stroke (as a major cardiovascular outcome)

Page 77 Extracted Terms:
**Key heart‑disease terms extracted from the guidelines and cited studies**

1. Coronary artery disease (CAD)  
2. Stable ischemic heart disease  
3. Coronary artery disease progression  
4. Stent implantation (drug‑eluting stent, bare‑metal stent)  
5. Target‑vessel ischemia  
6. Myocardial perfusion imaging (MPI)  
7. Single‑photon emission computed tomography (SPECT)  
8. Positron emission tomography (PET)  
9. Positron emission tomography‑based myocardial perfusion imaging  
10. Stress myocardial perfusion imaging  
11. Cardiac magnetic resonance (CMR) perfusion imaging  
12. Vasodilator stress cardiac magnetic resonance  
13. Fractional flow reserve (FFR)  
14. Coronary computed tomography angiography (CTA)  
15. Coronary flow reserve (CFR)  
16. Coronary angiography (invasive)  
17. Coronary CT angiography‑derived FFR (CT‑FFR)  
18. Exercise treadmill test (ETT)  
19. Dobutamine stress echocardiography (SE)  
20. Percutaneous coronary intervention (PCI)  
21. Coronary artery bypass graft (CABG) surgery  
22. Revascularization (early, routine, optimal)  
23. Optimal medical therapy (OMT)  
24. Anginal symptom burden  
25. Functional capacity (e.g., exercise capacity, peak VO₂)  
26. Health‑status outcomes (quality of life, angina relief)  
27. Cardiac hospitalizations & readmissions  
28. Sex/gender differences (female vs. male ischemia, outcomes)  
29. Hybrid imaging (PET/SPECT with CT, MRI)  
30. Prognostic risk scores (e.g., SYNTAX score, ISCHEMIA, Heart Team decision tools)  
31. Blood‑flow metrics (global and regional myocardial blood flow, perfusion reserve)  
32. Myocardial scar / late‑gadolinium enhancement  
33. Rest‑ventricular ejection fraction (LVEF)  
34. Coronary artery disease risk stratification  
35. Therapeutic benefit prediction (for revascularization vs. medical therapy)  
36. Diabetes‑related CAD management (BARI‑2D, type‑2 diabetes interventions)  
37. Advanced kidney disease in CAD context  
38. Artificial intelligence‑based perfusion mapping  
39. Heart team multidisciplinary decision making  

These terms capture the clinical concepts, diagnostic modalities, therapeutic strategies, risk stratification tools, and patient populations discussed in the provided text.

Page 78 Extracted Terms:
**Key heart‑disease related terms extracted from the document**

- AHA/ACC/ACCP/ASPC/NLA/PCNA Chronic Coronary Disease Guideline  
- 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Chronic Coronary Disease Guideline  
- Coronary artery disease (CAD)  
- Stable coronary disease  
- Unstable angina  
- Ischemic heart disease (IHD)  
- Coronary ischemia  
- Myocardial ischemia  
- Microvascular dysfunction  
- Coronary microvascular dysfunction  
- Coronary flow reserve (CFR)  
- Fractional flow reserve (FFR)  
- FFR derived from computed tomography angiography (FFR‑CT)  
- Percutaneous coronary intervention (PCI)  
- Coronary bypass graft surgery (CABG)  
- Bypass graft surgery  
- Coronary angiography  
- Stress myocardial perfusion imaging  
- Myocardial perfusion single‑photon emission computed tomography (SPECT)  
- Positron emission tomography (PET) – myocardial perfusion  
- Rubidium‑82 PET imaging  
- Technetium‑99m sestamibi SPECT  
- Exercise treadmill test (ETT)  
- Exercise stress echocardiography  
- Stress cardiac magnetic resonance (CMR)  
- Vasodilator stress CMR  
- Adenosine stress myocardial perfusion scintigraphy  
- Prognostic value  
- Risk stratification  
- Prognostic score  
- Predictive model for long‑term survival  
- Clinical outcomes  
- Long‑term survival  
- Cardiovascular mortality  
- Cardiac events  
- Left ventricular ejection fraction (LVEF)  
- Left ventricular dysfunction  
- Global longitudinal strain (GLS) – implied by LV function tests  
- Exercise capacity  
- Ischemia severity  
- Scar burden  
- Transient ischemic dilation ratio  
- PROMISE minimal‑risk tool  
- ISCHEMIA trial results  
- BARI 2D trial results  
- Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D)  
- ISCHEMIA trial  
- Coronary risk factors  
- Women‑specific ischemia risk  
- Gender‑related differences in imaging limits  
- Diabetes mellitus—impact on ischemia prognosis  

These terms capture the central concepts, diagnostic tools, interventions, prognostic metrics, and guideline references related to heart disease that appear throughout the provided text.

Page 79 Extracted Terms:
- Coronary artery disease  
- Stable coronary disease  
- Coronary disease (general)  
- Angina  
- Chronic angina  
- Stable ischemic heart disease  
- Myocardial ischemia  
- Myocardial infarction  
- Acute coronary syndrome  
- ST‑segment elevation myocardial infarction (STEMI)  
- Non‑ST‑segment elevation myocardial infarction (NSTEMI)  
- Coronary calcium score / coronary calcification  
- Coronary plaque  
- High‑risk plaque  
- Low‑attenuation plaque  
- Coronary computed tomography angiography (CCTA)  
- Coronary CT  
- Coronary magnetic resonance imaging (CMR)  
- Positron emission tomography (PET)  
- Myocardial perfusion imaging (MPI)  
- Stress perfusion imaging  
- Adenosine stress perfusion  
- Coronary flow reserve (CFR)  
- Percutaneous coronary intervention (PCI)  
- Coronary revascularization  
- Coronary artery bypass graft (CABG)  
- Invasive strategy  
- Conservative strategy  
- Anti‑anginal drugs (e.g., β‑blockers, nitrates, ranolazine, nifedipine)  
- β‑blocker therapy  
- Nifedipine (long‑acting)  
- Ranolazine therapy  
- Statin therapy  
- Lipid management  
- Low‑density lipoprotein (LDL) cholesterol  
- LDL testing / monitoring  
- Cholesterol endpoints  
- Atherosclerotic cardiovascular event  
- Heart failure  
- Left ventricular dysfunction  
- Dilated cardiomyopathy  
- Angina prevalence  
- Angina under‑recognition  
- Angina quality of life  
- Depression / depressive symptoms  
- Health‑related quality of life (HRQoL)  
- Quality of life (QoL)  
- Mortality  
- Morbidity  
- Prognostic value  
- Risk stratification  
- Risk factor management  
- Pharmacologic therapy  
- Medical therapy  
- Cardiovascular outcomes  
- Clinical guideline  
- Imaging modalities (CT, CMR, PET, MPI)  
- Coronary artery disease management  
- Coronary angiogram  
- Clinical statement  
- 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Chronic Coronary Disease Guideline  
- PROMISE trial  
- SCOT‑HEART trial  
- COURAGE trial  
- MERLIN‑TIMI 36 trial  
- ACTION trial  
- FAME (referenced in other literature)  
- ESP‑CAD trial  
- EUROASPIRE IV survey  
- ORBITA medication‑adherence sub‑study  
- Health literacy  
- Health education  
- Telehealth medication adherence  
- Patient‑reported outcomes  
- Physician‑estimated outcomes  
- Angina prevalence and provider evaluation (APPEAR) study  
- Health‑benefit outcomes study  
- Long‑term prognosis after myocardial infarction  
- Registry data  
- Multi‑center clinical studies  
- Diagnostic accuracy studies  
- Outcome studies  
- Prognosis studies  
- Efficacy studies  
- Randomized controlled trials (RCTs)  
- Clinical outcomes studies  
- Observational cohort studies  
- Patient registry studies  
- Quality improvement metrics  

*(All terms are those found explicitly or implicitly within the provided guideline text and directly relate to heart disease, its diagnosis, management, outcomes, and studies.)*

Page 80 Extracted Terms:
- Coronary artery bypass graft (CABG)  
- Coronary artery bypass surgery  
- Acute coronary syndromes (ACS)  
- Angina  
- Seattle Angina Questionnaire  
- Coronary heart disease  
- Systolic heart failure  
- Chronic heart failure  
- Hypertension  
- Hyperlipidemia  
- Lipid management  
- Type 2 diabetes mellitus  
- Diabetes mellitus  
- Cardiovascular risk  
- Cardiovascular disease (CVD)  
- Cardiovascular disease prevention  
- Cardiovascular risk management  
- Team‑based care  
- Pharmacist‑led interventions  
- Nurse‑led interventions  
- Multidisciplinary risk assessment and management  
- Multidisciplinary care program  
- Shared decision making  
- Patient education  
- Lifestyle disease prevention  
- Blood‑pressure control  
- Cardiovascular event prevention  
- Secondary prevention of heart failure  
- Remote algorithm‑based cardiovascular risk management  
- Digital care transformation in cardiovascular health  
- Clinical outcomes in cardiac patients  
- Quality of life in cardiac care  
- Cost‑effectiveness of collaborative care in cardiology  
- Blood‑pressure management in diabetes  
- Cardiovascular health promotion  

---

Page 81 Extracted Terms:
**Key terms related to heart disease**

- Coronary heart disease  
- Coronary artery disease  
- Chronic coronary disease  
- Myocardial infarction (MI)  
- Heart failure  
- Cardiac arrest  
- Cardiovascular disease (CVD)  
- Cardiovascular outcomes  
- Cardiovascular risk  
- Cardiovascular screening  
- Atherosclerosis  
- Ischemic heart disease  
- Angina  
- Percutaneous coronary intervention (PCI)  
- Coronary artery bypass grafting (CABG)  
- Beta‑blocker therapy  
- Medication adherence  
- Health literacy  
- Shared decision making  
- Decision aids  
- Framingham risk score  
- Social determinants of cardiovascular disease  
- Cardiovascular team‑based care  
- Cardiovascular prevention (primary & secondary)  
- Cardiac rehabilitation  
- Cardiovascular health equity  
- Community health workers in cardiovascular screening  
- ENRICHD trial  
- SWEDEHEART registry  
- AHA/ACC/ACCP/ASPC/NLA/PCNA chronic coronary disease guideline  
- ACC/AHA guideline on primary prevention of cardiovascular disease  
- American Heart Association impact goal  
- Cardiovascular risk assessment  

These terms capture the core biomedical, clinical, and health‑systems concepts discussed in the provided guideline and related literature.

Page 82 Extracted Terms:
**Key terms related to heart disease**

- Chronic coronary disease  
- Myocardial infarction (MI)  
- Acute myocardial infarction  
- ST‑segment elevation myocardial infarction (STEMI)  
- Coronary artery disease (CAD)  
- Coronary ischemia / suspected coronary disease  
- Coronary heart disease  
- Cardiovascular disease (CVD)  
- Cardiovascular complications  
- Cardiovascular events  
- Cardiovascular outcomes  
- Cardiac rehabilitation  
- Cardiac rehabilitation attendance / completion / access  
- Cardiometabolic risk factors  
- Blood pressure (hypertension)  
- Dietary sodium and potassium intake/excretion  
- Dietary fiber intake  
- Saturated fat intake  
- Trans fat intake  
- Omega‑3 fatty acids (n‑3 fatty acids)  
- Vitamin D supplementation  
- Vitamin E supplementation  
- Vitamin C & E supplementation (antioxidants)  
- Calcium/vitamin D supplementation  
- Multivitamin‑mineral supplementation  
- Beta‑carotene supplementation  
- Mediterranean‑style diet (primary & secondary prevention of CVD)  
- DASH diet (Dietary Approaches to Stop Hypertension)  
- Dietary fat intake (total, saturated, trans)  
- Nutrient‑related risk of cardiovascular disease  
- Dietary supplement use and cardiovascular risk  

These terms represent the main diseases, interventions, and modifiable risk factors pertaining to heart disease as highlighted in the provided guideline excerpts.

Page 83 Extracted Terms:
- Chronic Coronary Disease  
- Chronic Coronary Syndromes  
- Chronic Stable Angina  
- Coronary Artery Disease (CAD)  
- Acute Coronary Syndrome (ACS)  
- Acute Myocardial Infarction  
- Myocardial Infarction  
- Atherosclerotic Cardiovascular Disease  
- Coronary Heart Disease  
- Cardiovascular Disease  
- Cardiovascular Risk  
- Cardiovascular Outcomes  
- Cardiovascular Health  
- Cardio‑protective Diet  
- Cardio‑vascular Outcomes  
- Cardiovascular Mortality  
- Cardiovascular Events  
- Cardiometabolic Disease (as a risk factor)  
- Coronary Microcirculation (in the context of coronary pathophysiology)

Page 84 Extracted Terms:
- Coronary heart disease  
- Coronary artery disease  
- Acute coronary syndrome  
- Myocardial infarction (heart attack)  
- Ischemic heart disease  
- Atherosclerosis  
- Cardiovascular disease  
- Cardiovascular events  
- Cardiovascular outcomes  
- Cardiovascular risk  
- Cardiac rehabilitation  
- Hypertension  
- Depression  
- Anxiety  
- Stress (psychological stress)  
- Smoking / tobacco use  
- Nicotine  
- Electronic cigarettes (e‑cigarettes)  
- Passive smoking (second‑hand smoke)  
- Smoking cessation  
- Life’s Simple 7 (cardiovascular metrics)

Page 85 Extracted Terms:
**Key terms related to heart disease extracted from the text**

- Cardiovascular disease  
- Coronary heart disease (CHD)  
- Chronic coronary disease  
- Myocardial infarction (MI) / acute myocardial infarction  
- Ischemic heart disease  
- Heart disease  
- Coronary artery disease (CAD)  
- Cardiovascular events  
- Cardiovascular risk factors  
- Cardiovascular outcomes  
- Cardiovascular mortality  
- Cardiovascular safety  
- Cardiovascular toxicity  
- Cardiovascular effects  
- Arterial stiffness  
- Oxidative stress  
- Endothelial dysfunction  

**Behaviours / exposures**

- Tobacco smoking  
- Cigarette smoking  
- Second‑hand smoke (passive smoking)  
- Electronic cigarettes (e‑cigarettes)  
- Vaping / electronic nicotine‑delivery devices  
- Use of smokeless tobacco (e.g., snus, snuff)  
- Smoking cessation  
- Nicotine replacement therapy (patch, gum, lozenge)  
- Varenicline (partial nicotine agonist)  
- Bupropion (nicotine replacement)  

**Substance use**

- Alcohol use / alcohol consumption  
- High‑risk drinking  
- Binge drinking  
- Marijuana / cannabis / medical marijuana  
- Cocaine  
- Opioid use (including opioid‑associated out‑of‑hospital cardiac arrest)  

**Clinical conditions / syndromes**

- Acute coronary syndrome  
- Myocardial infarction after alcohol binge  
- Cardiovascular effects of cocaine  
- Cardiovascular effects of opioid use  
- Cardiovascular effects of marijuana  
- Cardiovascular effects of electronic nicotine‑delivery  
- Cardiovascular effects of second‑hand smoke  

**Interventions / policies**

- Tobacco cessation interventions  
- Pharmacological smoking cessation therapies (nicotine patch, varenicline, bupropion)  
- Behavioral support for smoking cessation  
- Expert consensus decision pathways for tobacco cessation  
- Cardiovascular safety of nicotine replacement in patients with CAD  

**Study / evidence descriptors**

- Systematic review  
- Meta‑analysis  
- Randomized controlled trial (RCT)  
- Cohort study  
- Prospective observational study  
- Retrospective analysis  

These terms capture the core concepts of heart (cardiovascular) disease, its risk factors, clinical manifestations, and related interventions as presented in the provided guideline text.

Page 86 Extracted Terms:
- Atherosclerotic cardiovascular disease (ASCVD)  
- Coronary heart disease (CHD) / Coronary artery disease (CAD)  
- Myocardial infarction (MI)  
- Acute coronary syndrome (ACS)  
- ST‑segment elevation myocardial infarction (STEMI)  
- Non‑ST‑segment elevation myocardial infarction (NSTEMI)  
- Cocaine‑associated myocardial infarction  
- Coronary artery bypass grafting (CABG)  
- Percutaneous transluminal angioplasty (PTCA)  
- Lipid‑lowering therapy (statins, ezetimibe, PCSK9 inhibitors)  
- Statin therapy  
- PCSK9 inhibitor therapy (alirocumab, evolocumab)  
- LDL‑cholesterol (LDL‑C) management  
- Hypercholesterolemia / Familial hypercholesterolemia  
- Lipid monitoring / lipid testing  
- Secondary prevention of coronary disease  
- Cardiovascular events (e.g., death, stroke, MI)  
- Cardiac rehabilitation (CR)  
- Sexual activity–related cardiovascular risk  
- Erectile dysfunction (in cardiovascular patients)  
- Hypertension (as a cardiovascular comorbidity)  
- Platelet activation (in drug‑induced cardiac events)

Page 87 Extracted Terms:
- Chronic coronary disease  
- Coronary artery disease  
- Acute coronary syndrome  
- Myocardial infarction  
- Peripheral artery disease  
- Atherosclerotic cardiovascular disease (ASCVD)  
- Familial hypercholesterolemia  
- Low‑density lipoprotein cholesterol (LDL‑C)  
- High‑density lipoprotein cholesterol (HDL‑C)  
- Hypertriglyceridemia  
- Lipoprotein(a)  
- Oxidized low‑density lipoprotein  
- Cardiovascular risk reduction  
- Statin therapy  
- Statin intolerance  
- Statin‑associated muscle symptoms (SAMS)  
- PCSK9 inhibitors (evolocumab, alirocumab)  
- Ezetimibe (not explicitly cited but related to LDL‑C lowering)  
- Icosapent ethyl (EPA)  
- Bempedoic acid  
- Inclisiran  
- Niacin (with or without laropiprant)  
- B vitamins and omega‑3 fatty acids (cardiovascular effects)  
- Blood‑pressure management (hypertension)  
- Weight loss, sodium reduction, dietary patterns (DASH)  
- Exercise training for blood‑pressure control  
- Alcohol consumption reduction  
- Lipid‑profiling methods (Friedewald formula, direct LDL measurement)  
- ACC/AHA/ACC/ACCP/ASPC/NLA/PCNA guideline  
- AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on cholesterol  
- ACC/AHA hypertension guideline  
- National Lipid Association expert panel on familial hypercholesterolemia  
- FDA‑approved lipid‑lowering drugs  

*(All terms are directly related to heart‑disease pathology, prevention, diagnosis, or treatment as referenced in the cited guidelines and trials.)*

Page 88 Extracted Terms:
- Chronic Coronary Disease  
- AHA/ACC/ACCP/ASPC/NLA/PCNA Chronic Coronary Disease Guideline  
- DASH (Dietary Approaches to Stop Hypertension) diet / DASH eating plan  
- Blood pressure (high, systolic, diastolic)  
- Intensive blood‑pressure control  
- SPRINT trial (Subpopulation)  
- Perindopril (ACE inhibitor)  
- Ramipril (ACE inhibitor)  
- Angiotensin‑converting‑enzyme inhibitor  
- Angina (stable angina)  
- Coronary artery disease (CAD)  
- Myocardial infarction (MI)  
- Acute myocardial infarction  
- Beta‑blocker / β‑adrenergic antagonist (metoprolol, atenolol, isoproterenol)  
- Beta‑blockade after myocardial infarction  
- Hypertension (arterial hypertension)  
- Primary and secondary prevention of cardiovascular disease  
- Atherosclerotic vascular disease  
- Stable ischemic heart disease (SIHD)  
- Cardiac events (coronary events)  
- Cardiovascular outcomes / cardiovascular morbidity / mortality  
- Cardiac outcomes in diabetes (type 2)  
- High cardiovascular risk  
- Sodium intake / low‑sodium diet  
- Heart failure (HF)  
- Sodium‑glucose cotransporter‑2 (SGLT2) inhibitors (empagliflozin, canagliflozin, dapagliflozin, ertugliflozin)  
- Glucagon‑like peptide‑1 (GLP‑1) receptor agonists (liraglutide)  
- EMPA‑REG OUTCOME trial  
- CANVAS Program (canagliflozin)  
- DAPA‑HF (dapagliflozin)  
- CVD‑REAL Study  
- Lifestyle interventions for blood‑pressure control (aerobic exercise, isometric training, potassium supplementation)  
- Meta‑analysis of randomised controlled trials concerning cardiovascular risk  
- 2017 ACC/AHA/HF guideline for systolic blood‑pressure management in hypertension  
- 2013 ESH/ESC guideline for arterial hypertension  
- 2014 ACC/AHA/SCAI/STS guideline for stable ischemic heart disease  
- 2015 ACCF/AHA/HF statement on hypertension in patients with coronary artery disease  
- 2016 NHLBI guidance on DASH eating plan  
- Sodium‑glucose cotransporter‑2 inhibitor benefits in heart failure and mortality  
- GLP‑1 receptor agonist cardiovascular outcome trials  
- Hypertension management in elderly/elderly consensus documents  
- Isometric exercise training for blood‑pressure management  
- Dietary sodium reduction trials (e.g., 2001 N Engl J Med study)  
- Blood‑pressure lowering drugs (β‑blockers, ACE inhibitors, calcium antagonists, diuretics)  
- Cardiovascular mortality and vascular mortality risk with blood pressure changes.

Page 89 Extracted Terms:
Heart Failure  
Heart Failure with Reduced Ejection Fraction  
Heart Failure with Preserved Ejection Fraction  
Heart Failure with Mildly Reduced Ejection Fraction  
Reduced Ejection Fraction  
Preserved Ejection Fraction  
Acute Coronary Syndrome  
Myocardial Infarction  
Reperfusion Injury  
Cardiovascular Outcomes  
Cardiovascular Events  
Cardiovascular Death  
Mortality  
Chronic Coronary Disease  
Ejection Fraction  

Page 90 Extracted Terms:
Chronic Coronary Disease; Coronary Heart Disease; Cardiovascular Disease; Myocardial Infarction; Heart Failure; Atherosclerosis; Coronary Artery Disease; Coronary Stenosis; Cardiovascular Outcomes; Major Adverse Cardiovascular Events; Metabolic Syndrome; Obesity; Central Obesity; Waist Circumference; Body Mass Index; Type 2 Diabetes; Metabolic Surgery; Bariatric Surgery; Liposuction; Cardiac Rehabilitation; Exercise‑Based Rehabilitation; High‑Intensity Interval Training; Cardiac Allograft Vasculopathy; Atrial Fibrillation; Coronary Calcium Score; Coronary Angiography; Cardiac CT; Cardiovascular Risk Factors; Cardiovascular Mortality; Cardiovascular Morbidity; Coronary Lesion; Coronary Disease Management; Cardiac Exercise Capacity; Cardiovascular Exercise Tolerance; Cardiovascular Risk Assessment; Cardiovascular Disease Prevention; Coronary Heart Disease Prevention.

Page 91 Extracted Terms:
- Cardiac Rehabilitation  
- Heart Failure  
- Coronary Artery Disease  
- Myocardial Infarction  
- Stable Angina  
- Spontaneous Coronary Artery Dissection  
- Heart Transplant  
- Cardiac Allograft Vasculopathy  
- Cardiovascular Disease  
- High‑Intensity Interval Training (HIT)  
- Resistance Training  
- Exercise‑Based Therapy  
- Telehealth Interventions  
- Physical Activity  
- Medication Adherence  
- Cardiovascular Risk Factors  
- Blood Pressure  
- Mortality  
- Long‑Term Survival  
- Readmissions  
- Health Service Expenditures  
- Cost‑Effectiveness  
- Secondary Prevention  
- Risk‑Factor Control  
- Exercise Training  
- Percutaneous Coronary Angioplasty  
- Population‑Based Study  
- Randomized Controlled Trial  
- Systematic Review  
- Meta‑Analysis  
- Clinical Guidelines  
- AHA/ACC/ACC/ASPC/NLA/PCNA Chronic Coronary Disease Guideline  
- 2022 AHA/ACC/HFSA Guideline for Heart Failure Management  

(Note: Each term is a key concept related to heart disease extracted from the provided text.)

Page 92 Extracted Terms:
- Coronary artery disease  
- Coronary heart disease  
- Myocardial infarction  
- Stroke (ischemic)  
- Heart failure with reduced ejection fraction  
- Cardiovascular disease  
- Cardiac rehabilitation  
- Antiplatelet therapy  
- Aspirin  
- Dual antiplatelet therapy  
- Drug‑eluting stent  
- High‑intensity interval training  
- Moderate‑intensity continuous training  
- Physical activity  
- Sedentary behaviour  
- Resistance training  
- Environmental exposures (air pollution, PM₂.₅, noise, heat‑waves)  
- Urban heat island  
- Ambient particulate matter exposure  
- Heat‑related hospitalisation  
- Cardiometabolic health  
- Exercise‑related acute cardiovascular events  
- Mortality risk  
- Cardiovascular morbidity and mortality statistics  

Page 93 Extracted Terms:
- Coronary artery disease  
- Chronic coronary disease  
- Acute coronary syndrome  
- Myocardial infarction  
- Heart failure  
- Left ventricular dysfunction  
- Atrial fibrillation  
- Percutaneous coronary intervention (PCI)  
- Stent thrombosis  
- Coronary artery bypass graft surgery  
- Dual antiplatelet therapy (DAPT)  
- Aspirin  
- Clopidogrel  
- Ticagrelor  
- Prasugrel  
- Thienopyridine  
- Antithrombotic therapy  
- Anticoagulant therapy  
- Rivaroxaban  
- Dabigatran  
- Apixaban  
- Direct oral anticoagulants (DOACs)  
- Proton pump inhibitors (PPIs)  
- Atherothrombotic events  
- Vascular events  
- Bleeding events  
- Ischemic heart disease  
- Cardiovascular disease (CVD)  
- National Heart Association/American College of Cardiology guidelines (e.g., ACC/AHA)  
- Network meta‑analysis  
- Randomized controlled trial (RCT)  



Page 94 Extracted Terms:
- Myocardial infarction  
- Acute myocardial infarction  
- Coronary artery disease  
- Chronic coronary disease  
- Chronic coronary syndromes  
- Atrial fibrillation  
- Stable angina  
- Percutaneous coronary intervention (PCI)  
- Drug‑eluting stent  
- Dual antiplatelet therapy (DAPT)  
- Antiplatelet therapy  
- Ticagrelor  
- Aspirin  
- Clopidogrel  
- Warfarin  
- Rivaroxaban  
- Dabigatran  
- Oral anticoagulation  
- Beta‑blocker therapy  
- Carvedilol  
- Metoprolol  
- Bisoprolol  
- Bu­cindolol  
- Heart failure  
- Ischemic heart disease  
- Left‑ventricular dysfunction  
- Left‑ventricular ejection fraction  
- Ventricular systolic dysfunction  
- Ventricular enlargement  
- Chronic heart failure

Page 95 Extracted Terms:
- Heart failure  
- Coronary artery disease  
- Myocardial infarction  
- Stable angina  
- Stable ischemic heart disease  
- Left ventricular dysfunction  
- Left ventricular ejection fraction (reduced & preserved)  
- Ventricular arrhythmias  
- Atrial fibrillation  
- Sudden cardiac death  
- Renin–angiotensin–aldosterone system (RAAS) inhibitors  
- Angiotensin‑converting enzyme (ACE) inhibitors  
- Angiotensin receptor blockers (ARBs)  
- Beta blockers (β‑blockers)  
- β‑adrenergic blockade  
- Antihypertensive agents  
- Perindopril  
- Enalapril  
- Ramipril  
- Captopril  
- Trandolapril  
- Quinapril  
- Telmisartan  
- Carvedilol  
- Nebivolol  
- Colchicine  
- Low‑dose colchicine therapy  
- Inflammation  
- Atherosclerosis  
- Cardiovascular events  
- Mortality  
- Morbidity  
- Secondary prevention of cardiovascular disease  
- Microvascular outcomes  
- Macrovascular outcomes  
- Chronic stable coronary disease  
- Prevention of events with ACE inhibition (PEACE)  
- Heart Outcomes Evaluation Prevention (HOPE‑3)  
- CIBIS‑II (Cardiac Insufficiency Bisoprolol Study)  
- MERIT‑HF (Metoprolol in Patients with Heart Failure)  
- BEST (Beta‑Blocker Evaluation of Survival Trial)  
- COPERNICUS (Captopril in Patients with Left Ventricular Dysfunction)  



Page 96 Extracted Terms:
- Acute myocardial infarction  
- Chronic coronary disease  
- Cardiovascular disease (general)  
- Heart failure  
- Stable angina pectoris  
- Refractory angina  
- Coronary artery disease  
- Ischemic heart disease  
- Coronary revascularization  
- Enhanced external counterpulsation (EECP)  
- Transmyocardial laser revascularization  
- Percutaneous laser myocardial revascularization  
- Myocarditis  
- Influenza vaccination  
- Pneumococcal vaccination  
- COVID‑19 vaccination  
- mRNA‑based COVID‑19 vaccination  
- Anti‑anginal drugs  
- Beta‑blockers  
- Calcium channel blockers  
- Nitrates  
- Ivabradine  
- Ranolazine  
- Metoprolol  
- Nifedipine  
- Diltiazem  
- Atenolol  
- Amlodipine  
- Colchicine  
- Colchicine–cardiovascular medication drug‑drug interactions  
- 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Chronic Coronary Disease Guideline  
- 2021 ESC guidelines on cardiovascular disease prevention  
- 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for stable ischemic heart disease  
- 2021 ACC/AHA/SCAI guideline for coronary artery revascularization  
- International Multicenter Angina Exercise (IMAGE) Study  
- Multifocal enhanced external counterpulsation study (MUST‑EECP)  
- Efficacy and safety of low‑dose colchicine after myocardial infarction  



Page 97 Extracted Terms:
**Key Heart Disease–Related Terms**

- Chronic Coronary Disease  
- Stable Ischemic Heart Disease  
- Coronary Artery Disease (CAD)  
- Coronary Artery Bypass Grafting (CABG)  
- Percutaneous Coronary Intervention (PCI)  
- Fractional Flow Reserve (FFR)  
- Instantaneous Wave‑Free Ratio (iFR)  
- Revascularization  
- Heart Team  
- Left‐Main Coronary Artery Disease  
- Ischemic Cardiomyopathy  
- Myocardial Infarction  
- Left Ventricular Dysfunction  
- Coronary Artery Bypass Surgery (CABG)  
- Drug‑Eluting Stents (e.g., Everolimus‑eluting)  
- Coronary Angiography  
- Coronary Artery Disease Management  
- Coronary Artery Disease Treatment Trials (ISCHEMIA, COURAGE, STICH, FAME, etc.)  
- Coronary Artery Bypass Graft Survival  
- Coronary Disease Quality‑of‑Life Outcomes  
- Coronary Disease Cost‑Effectiveness  
- Coronary Disease Evidence‑Based Guidelines (ACC/AHA/ACC, etc.)  
- Coronary Disease Meta‑analysis  
- Coronary Disease Clinical Outcomes  
- Coronary Disease Revascularization Decision Making  
- Coronary Disease Complex Stenoses  
- Coronary Disease Multivessel Disease  
- Coronary Disease Diabetes Mellitus Impact  
- Coronary Disease Stable Patients  
- Coronary Disease Invasive vs. Conservative Strategy  
- Coronary Disease Percutaneous vs. Surgical Outcomes  
- Coronary Disease Adverse Events (AMI, death, survival)  

These terms capture the core concepts, interventions, and outcomes discussed in the cited clinical statements and guidelines.

Page 98 Extracted Terms:
- Stable coronary disease  
- Invasive management  
- Conservative management  
- Percutaneous coronary intervention (PCI)  
- Coronary artery bypass grafting (CABG)  
- Fractional flow reserve (FFR)  
- Instantaneous wave‑free ratio (iFR)  
- Left‑main coronary artery disease  
- Unprotected left‑main stenosis  
- Bifurcation lesion  
- Drug‑eluting stents (DES)  
- Paclitaxel‑eluting stents  
- Everolimus‑eluting stents  
- Intravascular ultrasound (IVUS) guidance  
- Ischemic left ventricular dysfunction  
- Ischemia severity  
- Cardiovascular death  
- Non‑cardiovascular death  
- Symptomatic coronary artery disease  
- Three‑vessel disease  
- Severe coronary artery disease  
- Multivessel revascularization  
- Diabetes mellitus (in the context of coronary disease)  
- Patient‑reported pre‑procedural physical and mental health  
- Cost‑effectiveness analysis  
- Meta‑analysis of randomized trials  
- SYNTAX trial  
- NOBLE trial  
- PRECOMBAT trial  
- DKCRUSH‑V trial  
- DKCRUSH‑III study  
- DEFER study  
- FREEDOM study  
- Optim‑um registry (surgically ineligible patients)  
- Clinical outcomes  
- Long‑term survival  
- 10‑year follow‑up  
- 5‑year follow‑up  
- Prospective randomized open‑label study  
- Pooled individual patient data  
- Ranges of coronary artery disease severity  
- Clinical trial endpoints (mortality, morbidity, revascularization)  
- Revascularization strategies  

These terms capture the key concepts and clinical entities related to heart disease discussed in the provided guideline references.

Page 99 Extracted Terms:
- Chronic Coronary Disease  
- AHA/ACC/ACCP/ASPC/NLA/PCNA Chronic Coronary Disease Guideline  
- Coronary Revascularization  
- Percutaneous Coronary Intervention (PCI)  
- Coronary Artery Bypass Grafting (CABG)  
- Left Main Coronary Artery Disease  
- Spontaneous Coronary Artery Dissection (SCAD)  
- 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization  
- Coronary Intervention vs. Bypass Grafting outcomes  
- Med-Oriented and Surgery strategies for Multivessel Coronary Artery Disease (MASS II)  
- Dual Antiplatelet Therapy (DAPT) duration after PCI  
- Beta‑blockers and Antiplatelet agents in SCAD  
- Ischemia with Non‑Obstructive Coronary Arteries (INOCA)  
- Microvascular Angina  
- Vasospastic Angina  
- Invasive Coronary Function Testing (CorMicA trial)  
- Non‑Obstructive Coronary Artery Disease (NOCAD)  
- Coronary Angiography  
- Coronary Angioplasty (Percutaneous Coronary Angioplasty)  
- ST‑Segment Elevation Myocardial Infarction (STEMI)  
- Congestive Heart Failure (CHF)  
- Heart Failure with Preserved Ejection Fraction (HFpEF)  
- Heart Failure with Reduced Ejection Fraction (HFrEF)  
- AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for Chest Pain Evaluation  
- International Standardization of Diagnostic Criteria for Microvascular Angina  
- International Standardization of Diagnostic Criteria for Vasospastic Angina  
- Cardiac Rehabilitation after SCAD  
- Cardiac Rehabilitation after MI or angina  
- Fibromuscular Dysplasia (associated with SCAD)  
- Cervical Artery Abnormalities (fibromuscular dysplasia, dissection, aneurysm, tortuosity)  
- Pregnancy‑associated SCAD  
- Coronary Artery Tortuosity  
- Coronary Artery Aneurysm  
- Coronary Artery Dissection recurrence prevention.

Page 100 Extracted Terms:
- Chronic Coronary Disease  
- Heart Failure  
- Coronary Artery Disease (CAD)  
- Myocardial Infarction (MI)  
- Aortic Stenosis  
- Valvular Heart Disease (VHD)  
- Coronary Artery Revascularization  
- Percutaneous Coronary Intervention (PCI)  
- Coronary Artery Anomalies / Coronary Artery Abnormalities  
- Familial Hypercholesterolemia  
- Atherosclerotic Cardiovascular Disease (ASCVD)  
- Kawasaki Disease (congenital coronary involvement)  
- Inflammatory Arthritis (cardiovascular events)  
- Inflammatory Bowel Disease (acute coronary syndrome risk)  
- Cardio‑Oncology (cardiovascular effects of cancer therapies)  
- Radiation‑Induced Cardiovascular Disease  
- Vascular Toxicities of Cancer Treatments  
- Cancer‑Associated Cardiovascular Risk  
- Cardiovascular Risk Factors (hypertension, dyslipidemia, smoking, etc.)  
- Statin Therapy  
- Aspirin Therapy  
- Anticoagulation (for VTE prophylaxis in cancer)  
- Pregnancy in Women with Ischemic Heart Disease  
- Post‑pregnancy Cardiovascular Management  
- Postmenopausal Hormone Therapy and Cardiovascular Outcomes  
- Venous Thromboembolism (VTE) Prophylaxis in Cancer Patients  
- Contraception and Reproductive Planning in Women with Cardiovascular Disease  
- Cardiac Rehabilitation (including cardio‑oncology rehabilitation)  
- Endothelial Dysfunction  
- Ischemic Heart Disease (IHD)  
- Left Ventricular Ejection Fraction (reduced vs preserved)  
- Heart Failure with Reduced Ejection Fraction (HFrEF)  
- Heart Failure with Preserved Ejection Fraction (HFpEF)  
- Atrial Fibrillation (AF)  
- Atherosclerosis  
- Multi‑vessel Coronary Disease  
- Coronary Angiography  
- Coronary Angioplasty  
- Cardiogenic Shock  
- Revascularization Guidelines (ACC/AHA/SCAI)  
- Chronic Coronary Syndromes (CCS)  
- Acute Coronary Syndromes (ACS)  
- Long‑term CVD Outcomes (mortality, morbidity)  
- Risk‑Factor Modifications (diet, exercise, smoking cessation)  

These terms capture the main heart‑disease concepts referenced in the provided guideline excerpt.

Page 101 Extracted Terms:
- Cardiovascular disease  
- Coronary heart disease  
- Coronary artery disease (CAD)  
- Atherosclerosis  
- Angina pectoris  
- Myocardial infarction (MI)  
- Coronary artery bypass grafting (CABG)  
- Percutaneous coronary intervention (PCI)  
- Left‑main coronary artery disease  
- Multivessel coronary disease  
- Chronic coronary disease  
- Ischemic heart disease  
- Hypercholesterolemia  
- Familial hypercholesterolemia  
- Lipid‑lowering therapy  
- Statin therapy  
- Beta‑blocker therapy  
- Antithrombotic/anticoagulant therapy  
- Thromboembolism / thrombosis  
- Hemostatic alterations  
- Cardiac surgery (including CABG, PCI, coronary angiography)  
- Revascularization strategies  
- Renal injury after cardiac surgery  
- Quality of life in cardiac patients  
- Medication adherence/ compliance in cardiac disease  

(These are the principal terms related to heart disease that appear in the cited guidelines and studies.)

Page 102 Extracted Terms:
- Drug‑eluting stents  
- Coronary artery disease (CAD)  
- Percutaneous coronary intervention (PCI)  
- Dual antiplatelet therapy (DAPT)  
- Triple therapy (warfarin + aspirin + clopidogrel/ticagrelor)  
- Transradial coronary intervention  
- Coronary artery bypass grafting (CABG)  
- Minimally invasive direct coronary artery bypass  
- Bypass grafting with internal mammary arteries  
- Frailty (predictor of outcomes in CAD)  
- Sarcopenia (predicts adverse outcomes in CAD)  
- Malnutrition / nutritional index (predicts mortality post‑PCI)  
- Contrast‑induced acute kidney injury (CI-AKI)  
- Chronic kidney disease (CKD)  
- Contrast‑associated acute kidney injury (CA-AKI)  
- Coronary calcification in CKD  
- Atherosclerosis & vascular calcification (in CKD)  
- Statin therapy in CKD patients  
- Antiplatelet therapy in CKD patients  
- AHA/ACC/ACCP/ASPC/NLA/PCNA Chronic Coronary Disease Guideline  
- ACC/AHA/SCAI guideline for coronary artery revascularization  
- ISCHEMIA‑CKD study (invasive vs medical treatment for CKD)  
- Renal dysfunction & cardiovascular outcomes after myocardial infarction  
- Kidney disease as a risk factor for cardiovascular disease  
- Geriatric 5Ms (optimizing care in elderly cardiac patients)  
- Exercise‑based cardiac telerehabilitation  
- Home‑based mobile cardiac rehabilitation  
- SYNTAX score (age‑dependent impact on mortality post‑PCI)  
- Contrast‑induced nephropathy risk score (Mehran score)  
- Functional status measures in elderly cardiac patients  
- Long‑term outcomes after PCI vs CABG in octogenarians  
- Outcomes of percutaneous transluminal coronary angioplasty in chronic renal failure  
- Kidney disease management guidelines (NEOERICA, etc.)

Page 103 Extracted Terms:
**Key heart‑disease related terms extracted from the text**

- Myocardial infarction (MI) / Myocardial infarct  
- Coronary artery disease (CAD) / Chronic coronary disease  
- Coronary artery bypass grafting (CABG) / Coronary artery bypass graft (CABG)  
- Percutaneous coronary intervention (PCI) / Angioplasty  
- Revascularization  
- Acute coronary syndrome (ACS)  
- ST‑segment elevation myocardial infarction (STEMI)  
- Cardiac catheterization / Coronary angiography  
- Contrast‑induced nephropathy (CIN) – peri‑procedural renal injury related to cardiac procedures  
- Acute kidney injury (AKI) after coronary procedures  
- Cardiovascular disease (CVD) / Cardiovascular complications  
- Cardiovascular events / Cardiovascular risk  
- Atherosclerotic cardiovascular disease (ASCVD)  
- Heart disease / Heart‑disease statistics  
- Dyslipidemia / Hyperlipidemia / Hypertriglyceridemia / Blood cholesterol  
- Statin therapy / Lipid‑lowering therapy  
- Cholesterol management / Blood‑cholesterol guideline  
- HIV‑associated cardiovascular disease risks (e.g., abacavir, protease inhibitors, ritonavir, dolutegravir)  
- Coronary plaque formation / Coronary plaque stabilization  
- Coronary artery disease management in advanced kidney disease  
- Radial access vs. femoral access (transradial vs. transfemoral approach)  
- Post‑procedural complications of coronary interventions  
- Cardiovascular risk management in autoimmune disorders (rheumatoid arthritis, psoriasis, etc.)  

These terms capture the central heart‑disease concepts discussed across the cited guidelines and studies.

Page 104 Extracted Terms:
**Heart‑disease related terms identified in the text**

1. Chronic Coronary Disease  
2. Cardiac allograft vasculopathy  
3. Heart transplantation / heart transplant recipients  
4. Coronary artery disease (stable & acute)  
5. Percutaneous coronary intervention (PCI)  
6. Coronary artery bypass grafting (CABG)  
7. Statin therapy (e.g., simvastatin, pravastatin, atorvastatin)  
8. Aspirin use in transplant patients  
9. Everolimus‑eluting stents  
10. Sirolimus (rapamycin) therapy  
11. Paclitaxel‑eluting stents  
12. Calcineurin inhibitor elimination (e.g., cyclosporine, tacrolimus)  
13. High‑intensity interval training (exercise)  
14. Body‑mass‑index effects on transplant outcomes  
15. Intravascular ultrasound (IVUS) for graft assessment  
16. Coronary physiology assessment (e.g., fractional flow reserve)  
17. Coronary risk‑factor management  
18. Myocardial infarction (MI)  
19. Anginal symptoms / angina  
20. Myocardial ischemia  
21. Coronary heart disease (CHD)  
22. Secondary prevention of cardiovascular disease  
23. Depression in cardiac patients  
24. Telephone‑delivered health coaching  
25. Tele‑health interventions for acute coronary syndrome (ACS)  
26. Lifestyle‑focused interventions (diet, exercise, weight management)  
27. Text‑messaging adherence programs for CHD  
28. Clinical guidelines for chronic coronary disease (AHA/ACC/ACCP/ASPC/NLA/PCNA)  
29. ACC/AHA/SCAI guidelines for coronary artery revascularization  
30. International Society of Heart & Lung Transplantation (ISHLT) guidelines  
31. ESC Heart Failure guidelines (for heart transplant recipients)  
32. ESC Heart Failure outcomes reporting  
33. Cardiovascular drug‑drug interaction recommendations (statins)  

These terms encompass diseases, interventions, pharmacotherapies, procedural techniques, lifestyle strategies, and guideline references that are central to the clinical management of heart disease as presented in the material.

Page 105 Extracted Terms:
- Chronic Coronary Disease  
- Percutaneous Coronary Intervention (PCI)  
- Coronary Angiography  
- Coronary Artery Disease  
- Myocardial Infarction  
- Chronic Stable Angina  
- Coronary Heart Disease  
- Drug‑Eluting Stents  
- Revascularisation  
- Chronic Coronary Syndrome  
- Ischaemia  
- Heart Failure  
- Atherosclerotic Cardiovascular Disease  
- PCSK9 Inhibitors  
- Sacubitril‑Valsartan  
- Coronary Disease Secondary Prevention  
- Coronary Risk‑Factor Management  
- Coronary Imaging Follow‑up

(Note: Terms are extracted only as relevant to heart disease concepts.)

Page 106 Extracted Terms:
**Key heart‑disease related terms extracted from the text**

- Chronic Coronary Disease  
- Cardiovascular  
- Cardiovascular Disease Prevention  
- Cardiovascular Fellowship Program  
- Cardiologist  
- Cardiology  
- Heart  
- Heart Institute  
- Heart Health  
- Heart Health & Performance Program  
- Coronary  
- Lipid  
- Atherosclerosis  
- Cardiac  
- Clinical Guidelines  
- AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline  
- Journal of the American College of Cardiology (JACC)  
- European Heart Journal – Acute Cardiovascular Care  
- Current Atherosclerosis Reports  
- Current Cardiology Reports  
- American Heart Journal  
- Journal of Clinical Lipidology  
- World Heart Federation (WHF)  
- National Heart, Lung, and Blood Institute (NHLBI)  

These terms capture the primary disease concepts, specialty fields, and major publishing/committee entities related to heart disease that appear in the provided guideline document.

Page 107 Extracted Terms:
- Chronic Coronary Disease Guideline  
- Cardiology  
- Cardiac  
- Coronary  
- Cardiovascular  
- AHA (American Heart Association)  
- ACC (American College of Cardiology)  
- ACCP (American College of Clinical Pharmacology)  
- ASPC (American Society of Parenteral and Enteral Nutrition)  
- NLA (National Lipid Association)  
- PCNA (Primary Care Cardiovascular Nursing Association)  
- CDC (Centers for Disease Control and Prevention)  
- NIH (National Institutes of Health)  
- Circulation  
- Circulation: Cardiovascular Interventions  
- Circulation: Cardiovascular Quality and Outcomes  
- Journal of Cardiovascular Pharmacology  
- Journal of Clinical Lipidology  
- International Journal of Cardiology  
- JACC (Journal of the American College of Cardiology)  
- HeartFlow  
- Abbott  
- Boston Scientific  
- Edwards Lifesciences  
- Medtronic  
- Siemens  
- CathWorks  
- Neovasc Medical Inc.  
- Cardiac Critical Care  
- HeartHealth (Women‑Heart)  
- American Journal of Preventive Cardiology  

Page 108 Extracted Terms:
- Chronic Coronary Disease  
- Arrhythmia  
- Acute coronary syndrome (referenced as “Acute SOP/CP”)  
- Cardiovascular disease  
- Cardiology  
- Heartflow  
- Heart disease  
- National Forum for Heart Disease & Stroke Prevention (heart‑related focus)

Page 109 Extracted Terms:
- Chronic Coronary Disease  
- Heart Disease  
- Cardiovascular Medicine  
- Cardiovascular Division  
- Cardiology  
- Preventive Cardiology  
- Noninvasive Cardiac Imaging  
- Cardiac Magnetic Resonance (MRI)  
- Cardiac Computed Tomography (CT)  
- Cardiac Stress Laboratory  
- AHA (American Heart Association)  
- ACC (American College of Cardiology)  
- ASPC (American Society for Preventive Cardiology)  
- NLA (National Lipid Association)  
- PCNA (Prevention of Cardiovascular Disease Network)  
- Circulation (journal)  
- AHA/ACC/ACCP/ASPC/NLA/PCNA Chronic Coronary Disease Guideline 2023  
- Cardiac Magnetic Resonance Imaging (CMR)  
- Cardiovascular Magnetic Resonance  
- Cardiovascular Computed Tomography  
- Cardiac imaging  
- Cardiac imaging technology  
- Cardiac magnetic resonance imaging equipment  
- Cardiac computed tomography equipment  
- Cardiac stress testing  
- Cardiology editorial work / guidelines  
- Cardiovascular research  
- Cardiovascular clinical trials  
- Heart disease prevention  
- Cardiovascular risk assessment  



Page 110 Extracted Terms:
Chronic Coronary Disease  
Cardiology  
Cardiac  
Coronary  
Cardiovascular  
Heart  
Cardiac catheterization  
Angiography  
Interventions  
Cardiovascular drugs  
Heart disease  
Cardiac disease  
Coronary artery disease  
Prevention of cardiovascular disease  
AHA (American Heart Association)  
ACC (American College of Cardiology)  
NHLBI (National Heart, Lung, and Blood Institute)  
ESC (European Society of Cardiology)  
SCAI (Society for Cardiovascular Angiography and Interventions)  
WHF (World Heart Federation)  
PCNA (Preventive Cardiovascular Nurses Association)  
ASPC (American Society of Preventive Cardiology)  
ACCF (American College of Cardiology Foundation)  
ACCP (American College of Clinical Pharmacy)  
ASNC (American Society of Nuclear Cardiology)  
JACC (Journal of the American College of Cardiology)

Page 111 Extracted Terms:
- Chronic Coronary Disease  
- Heart disease  
- Coronary disease  
- Cardiovascular disease  
- Myocardial infarction  
- Thrombolysis in myocardial infarction (TIMI)  
- Lipid disorders  
- Family Heart  
- American Heart Association (AHA)  
- American College of Cardiology (ACC)  
- American College of Clinical Pharmacy (ACCP)  
- American Society of Preventive Cardiology (ASPC)  
- National Lipid Association (NLA)  
- Preventive Cardiovascular Nurses Association (PCNA)  
- Society of Thoracic Surgery (STS)  
- National Heart, Lung, and Blood Institute (NHLBI)

